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ABSTRACT

Opioids are among the most potent and widely used drugs for the management of chronic
pain. Chronic pain is exceedingly prevalent in individuals over 65 years of age but is undermanaged in this population, due in part to a lack of knowledge regarding the suitable dosing of
opioids for chronic pain management. The present experiments first seek to characterize the
impact of advanced age on opioid potency in male and female rats using intraplantar Complete
Freund's adjuvant (CFA), a clinically relevant model of inflammatory pain. We report that
advanced age and sex alter morphine modulation of persistent inflammatory pain, specifically,
morphine potency was highest in adult male rats (2mos), with a 2-fold rightward shift in the
dose-response curve for aged males (18mos), and females regardless of age. These findings
suggest that opioids have decreased anti-hyperalgesic potency in aged rodents compared to
adults, prompting us to determine the neural mechanisms underlying this attenuated response.
Morphine-induced analgesia is mediated primarily via binding to μ-opioid receptors
(MOR) within the midbrain periaqueductal gray (PAG), a critical site for descending pain
modulation. The present studies use cellular and pharmacological techniques to examine MOR
binding and signaling within the PAG. The data in this thesis thoroughly characterize the impact
of advanced and biological sex on PAG MOR expression, binding, and signaling within the PAG
in the presence of chronic inflammatory pain, and thus have significant implications for pain
management in the aged population. These studies contribute to our understanding of how
advanced age and sex alter morphine anti-hyperalgesia and enhance our knowledge of age- and
sex-induced changes in PAG MOR signaling. Our findings identify novel therapeutic targets to
improve opioid signaling in the aged brain and develop effective chronic pain management
strategies.
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1.1

INTRODUCTION

Chronic pain and pain management in the aged
Chronic pain, defined as severe pain persisting for longer than 3 months, is debilitating in

nature, negatively impacting mental health and contributing to the increased risk of premature
death (Patel et al., 2013; Treede et al., 2015; Domenichiello & Ramsden, 2019). It is among the
most commonly reported health issue in the United States, with greater than 20% of adults
experiencing chronic pain on a daily basis (Dahlhamer, 2018).
The United States population is rapidly aging. In 2019, 54 million Americans were 65 or
older, comprising 16% of the population. By 2040, this demographic is projected to reach 80
million, at which time individuals over 65 years will represent nearly 25% of the United States
population (Promoting Health for Older Adults | CDC, 2022). Those over 65 years of age
experience chronic pain at a higher rate than their adult counterparts; nearly 40% of individuals
over 65 report chronic pain (Larsson et al., 2017), and over 50% report experiencing at least one
chronic pain condition within the past year (Tsang et al., 2008), including pain associated with
arthritis, cancer, diabetes mellitus, and cardiovascular disease (Dahlhamer, 2018; Domenichiello
& Ramsden, 2019). Elderly individuals residing in assisted living facilities report higher rates of
chronic pain than community dwelling elderly, with upwards of 80% of nursing home residents
reporting chronic pain (Higgins et al., 2004; Stompór et al., 2019). Thus, there is a growing need
for adequate management of chronic pain in this vulnerable population (Miaskowski, 2011).
Chronic pain is typically managed by prescription medications called analgesics which
reduce the severity of symptoms (Manchikanti et al., 2010; Sullivan et al., 2010). Opioids,
including morphine and fentanyl, are among the most potent and commonly prescribed
analgesics for chronic pain management (Mercadante et al., 2019). However, despite elderly
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individuals suffering from chronic pain at a higher rate than young adults, chronic pain is
undermanaged in the aged demographic, due in part to a dearth of knowledge regarding proper
dosing and side effects of opioid use in the aged (B. A. Ferrell et al., 1990; Pergolizzi et al.,
2008; Campbell et al., 2010; Barnett et al., 2017). Multiple clinical factors contribute to the
undermanagement of pain in the elderly; most notable are under-reporting of pain intensity for
fear of being institutionalized, physician reluctance to prescribe opioids to elderly individuals
due to concerns over adverse side effects (including cognitive and physical impairment,
respiratory depression), and misconceptions regarding tolerance and addiction (Cavalieri, 2005;
Chau et al., 2008; Saunders et al., 2010; Miaskowski, 2011; Miaskowski et al., 2011; Reddy et
al., 2012; Dampier et al., 2013; Schiltenwolf et al., 2014; Naples et al., 2016; Prostran et al.,
2016). Studies that accurately assess the impact of advanced age on opioid analgesia are needed
to identify potential mechanisms by which advanced age impacts opioid analgesia, thereby
facilitating the development of therapeutics to effectively manage pain in this population while
concurrently minimizing the negative side effects associated with opioid consumption.

1.2

Mechanisms of pain and opioid analgesia in the central nervous system
Painful stimuli originating in the periphery are initially detected by nociceptors,

specialized sensory neurons with cell bodies in the dorsal root ganglion (DRG) and peripheral
processes that innervate joints, muscle, and skin. Nociceptors, or primary afferents, transmit
information from the periphery to the central nervous system to produce the sensory components
of pain. Nociceptors are divided into 3 main categories: Aδ-, Aβ-, and C-fibers. Myelinated fastconducting Aδ-fibers act as both thermal nociceptors that detect extreme temperatures and
mechanical nociceptors that detect intense pressure on the skin. Myelinated Aβ-fibers act
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primarily as mechanoreceptors but are also activated by noxious mechanical stimuli and noxious
heat (Djouhri & Lawson, 2004). Unmyelinated slow-conducting C-fibers act as polymodal
nociceptors that detect thermal, mechanical, and chemical stimuli. Noxious stimuli depolarize the
endings of Aδ-, Aβ-, and C-fibers via transient receptor potential (TRP) ion channels, and the
resultant action potentials are transmitted to the cell bodies or first-order pseudo-unipolar
neurons in the DRG. The central branches of these DRG neurons terminate in the dorsal horn of
the spinal cord: Aδ-fibers terminate preferentially within lamina I, II, and V; C-fibers terminate
within lamina I, and II; and Aβ fibers terminate within lamina IV. (Millan, 1999; Lemke, 2004;
Dubin & Patapoutian, 2010).
Nociceptive information predominantly ascends the spinal cord from the dorsal horn via
the spinothalamic tract which relays nociceptive, thermosensitive, and somatosensory
information. The axons of dorsal horn second order neurons cross the midline of the spinal cord
at the anterior white commissure, project to the medulla and pons, and terminate supraspinally
within thalamic nuclei. Third order thalamic nuclei relay nociceptive information to the
somatosensory cortex and limbic system. Nociceptive information also ascends the spinal cord
via the spinoreticular and spinomesencephalic pathways, projecting to the reticular formation and
the midbrain periaquectuctal gray (Ab Aziz & Ahmad, 2006; Garland, 2012; Groh et al., 2018).
The nociceptive input from the periphery that projects to higher-order brain regions is
subjected to tonic descending inhibition at the level of the dorsal horn of the spinal cord by the
descending pain modulatory pathway (Melzack & Wall, 1965; Garland, 2012). The midbrain
periaqueductal gray (PAG), the first region of the descending pain pathway, receives nociceptive
input from multiple supraspinal regions. Projections from the PAG descend to the rostral
ventromedial medulla (RVM), which sends bilateral projections via the dorsolateral funiculus to
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terminate within the dorsal horn of the spinal cord (Basbaum et al., 1978; Behbehani & Fields,
1979; Fields & Heinricher, 1985).
The PAG, and in particular the ventrolateral periaqueductal gray (vlPAG), contains mu
opioid receptors (MORs), proteins to which opioids bind to bring about the inhibition of
ascending pain signals (Martin, 1963; Wolozin & Pasternak, 1981; Jensen & Yaksh, 1986;
Morgan et al., 1992; Loyd et al., 2008). MORs are seven-transmembrane spanning proteins with
an extracellular N-terminal domain and an intracellular C-terminal domain (Herman et al., 2022).
MORs are G-protein coupled receptors (GPCRs), binding predominantly to inhibitory G-proteins
Gi/o (Goode & Raffa, 1997; Gintzler & Chakrabarti, 2004). Within the PAG, opioid binding to
GABAergic interneurons promotes an intracellular G-protein-mediated signaling cascade
whereby GABAergic neurons are hyperpolarized, inhibiting GABA release. Indeed, extracellular
GABA in the PAG is reduced following administration of morphine (Stiller et al., 1996). In the
absence of MOR binding, these GABAergic interneurons tonically inhibit the antinociceptive
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PAG-RVM descending pathway. Thus, opioid-induced hyperpolarization of PAG GABAergic
interneurons disinhibits the PAG-RVM descending pathway and enhances anti-nociceptive
projections to the dorsal horn of the spinal cord (Stiller et al., 1996; G. W. Pasternak, 2001;
Novak, 2007; Lau & Vaughan, 2014; Lueptow et al., 2018)(Figure 1.1).
1.2.1

Mechanisms of chronic inflammatory pain

Painful stimuli applied to the skin promote the local release of inflammatory mediators
including bradykinins, prostaglandins, and adenosine triphosphate (ATP) (H. Wang et al., 2005;
Amaya et al., 2013). Injury at the periphery activates not only nociceptive neurons but also
innate immune cells, particularly microglia. Activated microglia, which are observed in virtually
every known animal model of clinical pain, react to the presence of pathogens, including nitric

Figure 1.1 Descending pain modulatory pathway, critical role of PAG MOR
Afferent signals are inhibited by the downstream pain modulatory pathway. Opioids act at u-opioid
receptors (MOR) within the periaqueductal gray (PAG) to inhibit pain at the dorsal horn of the spinal cord
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oxide, substance P, and prostaglandins that are released at the time of injury (Watkins et al.,
2009). These proinflammatory substances bind to receptors called toll-like receptors (TLRs) and
in particular TLR4, located primarily on the surface of microglia. Binding to microglial toll-like
receptor 4 (TLR4) results in the transition of microglia from a resting state to an activated state, a
process called reactive gliosis (Watkins & Maier, 2003; Hutchinson et al., 2008; Watkins et al.,
2009). In their activated state, microglia release pro-inflammatory molecules including cytokines
(e.g. interleukins 1 and 6, (IL-1, IL-6), and tumor necrosis factor (TNF)), chemokines (e.g. IL-8,
CCL2, and CCL5), cyclooxygenase-2 (COX-2), prostaglandins, and reactive oxygen species
(ROS) (Bonizzi & Karin, 2004). Together, these molecules down-regulate inhibitory GABAA
receptors, up-regulate excitatory neuronal AMPA and NMDA receptors, and decrease glutamate
transporter activity, effectively increasing neural excitability and opposing opioid
hyperpolarization (Watkins et al., 2005; Yan et al., 2014; Eidson et al., 2017).
One experimental method used to induce inflammatory pain in rodents is the intraplantar
administration of the mycobacteria Complete Freund’s Adjuvant (CFA). Intraplantar CFA is one
of the most commonly used procedures to induce a persistent pain state and has been shown to
reliably mimic the time course of postoperative pain as well as other types of persistent pain due
to injury (Millan et al., 1988; Stein et al., 1988). The localized inflammation resulting from
intraplantar CFA produces hyperalgesia that parallels the clinical experience of tissue injury
induced by trauma or disease, for which morphine is typically prescribed. CFA-induced
hyperalgesia is present within 2-6 hours of injection and is still evident 7-14 days following
administration (Millan et al., 1988; Stein et al., 1988; Philippe et al., 1997; Goff et al., 1998; X.
Wang et al., 2006).
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The activation of glial cells directly contributes to the robust hyperalgesia produced by
inflammatory CFA (Watkins et al., 1994; Raghavendra et al., 2004; Sorge et al., 2011). Indeed,
inhibition of glial function or the blockade of pro-inflammatory cytokine release reverses
hyperalgesia (Maier & Watkins, 1998; Plunkett et al., 2001; Raghavendra et al., 2004;
Hutchinson et al., 2008), supporting a model whereby neurons and glia engage in bidirectional
communication to promote hyperalgesia following inflammatory pain. Both the inhibition of
microglial function and the blockade of pro-inflammatory molecule release prevent the
development of hyperalgesia (Maier & Watkins, 1998; Ledeboer et al., 2005; Hutchinson et al.,
2008).
1.3

Studies of opioid analgesia, effects of advanced age and biological sex
Several clinical studies have examined how the aging process affects opioid potency;

unfortunately, conclusions drawn across studies remain inconsistent. For example, in postoperative cancer patients, morphine promoted greater pain relief in older (aged 50-89) versus
younger patients (18-29) (Kaiko, 1980), and aged men self-administered lower concentrations of
morphine to manage post-surgical pain compared to young men (Gagliese & Katz, 2003).
Alternatively, a clinical assessment of opioid potency for cancer pain management in men and
women found that morphine analgesia was attenuated in the aged. Here, analysis of self-reported
pain and oral morphine concentration in 577 subjects ranging from age 17 to 91 revealed that
men and women >74 years of age required higher daily doses of morphine to manage cancer pain
(478.8 mg/day) compared to men and women <65 years of age (353.3 mg/day) (Loick et al.,
2000).
This lack of consensus on how advanced age impacts opioid analgesia is due in large part
to limitations of clinical trials and consequent issues in the interpretation of results. More
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specifically, a primary limitation is that opioids are prescribed in the clinic to alleviate severe and
persistent pain resulting from injury, surgery, or disability, but the majority of studies on aging
and opioid efficacy were conducted on patients experiencing acute (rather than chronic) pain
(Aubrun et al., 2005; Gagliese & Katz, 2003; Lautenbacher, 2012). Further, aged patients present
high rates of comorbid health conditions, including cardiovascular disease, diabetes, and high
blood pressure, all of which entail the use of concomitant medications that may attenuate or
potentiate the analgesic effects of opioids (Naples et al., 2016; Prostran et al., 2016). In addition,
aged populations underreport pain in a clinical setting, likely due to fears of institutionalization
and concerns with addiction and overdose (Reddy et al., 2012). For example, many clinical
studies use the McGill Pain Questionnaire, a verbally-based self-assessment consisting of
questions regarding the affective qualities and intensities of pain (Perez‐Lloret et al., 2016).
Younger men are more likely to report pain using this type of assessment in comparison to a
visual analog scale, in which there are no age differences in reporting (Gagliese & Katz, 2003).
To control for the issues associated with clinical studies, researchers have turned to
rodent models to assess the impact of advanced age on opioid potency. Unfortunately, very few
studies have been conducted that use aged animals, likely due to the increased costs in
maintaining a long-term colony (Jackson et al., 2017). Of the studies that have been conducted,
the results are often contradictory and thus, like the clinical studies, fail to provide a consensus
on the impact of advanced age on opioid analgesia. For example, Chan and Lai reported that
morphine (10mg/kg; sc) significantly increased the hot plate latency in adult male rats (54 days
old), while this dose was without effect in middle aged (162 days) or elderly (327 days) rats
(Chan & Lai, 1982). In female rats aged 4, 9, 14, 19, and 24 months, morphine was more
effective in lowering withdrawal rates in the jump and tail flick tests in younger rats (Kramer &
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Bodnar, 1986). Additionally, Crisp et al. reported that rats aged 26 months exhibited reduced
opioid antinociception compared to rats aged 5-6 months, as evidenced by a rightward shift in
the DAMGO dose-response curve measured using a tail-flick assay (Crisp et al., 1994). Similar
results were reported by Islam et al., with male and female rats exhibiting higher morphine EC50
doses (lower potency) at 18 months versus 6 months of age (Islam et al., 1993). However, not all
studies on rodents reveal age-dependent reductions in opioid potency. In a review of relevant
literature on opioid analgesia, Gagliese and Melzack (2000) report that while the results of
several studies suggest a decline in morphine analgesic potency with advanced age, several
studies report no impact or even an improvement in opioid analgesia as a function of advanced
age (Gagliese & Melzack, 2000).
Preclinical studies of morphine analgesia using rodents also present limitations that
mirror some of the issues associated with clinical studies. Notably, researchers typically utilize
acute (tail flick, hot plate) rather than persistent pain assays, and more often than not, elect to use
exclusively male subjects in their studies (Chan & Lai, 1982; Kavaliers et al., 1983; Smith &
Gray, 2001; Jourdan et al., 2002). As morphine is prescribed for the alleviation of persistent (and
not acute) pain, it is important that experiments accurately model chronic pain conditions that
necessitate opioid prescriptions in order to develop a definitive picture of the impact of advanced
age on opioid potency.
The existence of sex differences in opioid analgesia in the clinic remains controversial.
Although some clinical studies report no sex difference in the analgesic efficacy of
opioids(Sarton et al., 2000; Fillingim et al., 2005; Bijur et al., 2008), other studies report that
opioids exhibit decreased analgesic efficacy in women (Cepeda & Carr, 2003; Miller & Ernst,
2004). Importantly, these results are dependent on the setting (clinic versus laboratory), duration
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of pain (acute versus chronic), and type of pain (visceral, inflammatory, or orofacial) for which
opioids are administered. Preclinical studies using rodent models are more consistent, with most
studies reporting that morphine is more efficacious in modulating persistent pain in males than
females. Indeed, using a variety of acute and chronic pain assays, researchers have shown that
morphine’s median effective dose in female rodents is approximately twice the concentration
needed for males to achieve comparable levels of pain relief (Kepler et al., 1989; Cicero et al.,
2002; Ji et al., 2006; Loyd & Murphy, 2006; Loyd et al., 2008; Posillico et al., 2015). Sex
differences in the antinociceptive effects of opioids have been reported for multiple MOR
agonists, including levorphanol, dezocine, buprenorphine, butorphanol, and nalbuphine. (Barrett
et al., 2002).
The mechanisms underlying the attenuated response to morphine in females are not
known, however several contributing factors have been identified, including sex differences in
MOR expression, and sex differences in PAG-RVM projections (Loyd et al., 2007, 2008).
Recent studies by our laboratory tested the hypotheses that sex differences in MOR-mediated
analgesia are driven by sex differences in the activity of microglia. Morphine and other opioids
bind not only to neuronal MOR but also to microglial TLR4; morphine binding to TLR4 within
the PAG and spinal cord induces cytokine release, resulting in the attenuation of morphine
analgesia (Eidson & Murphy, 2013; Eidson et al., 2017). Blockade of PAG TLR4 signaling, and
the ensuing cytokine production, enhances morphine-induced analgesia (Eidson & Murphy,
2013; Eidson et al., 2017; Doyle et al., 2017). Although no sex differences in basal microglia
expression (density) are present within the PAG, the percentage of microglia showing an
‘activated’ phenotype at baseline is significantly higher in females than males, suggesting that
sex differences in microglia phenotype within the PAG contribute to the sexually dimorphic
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effects of morphine (Doyle et al., 2017; Doyle & Murphy, 2017). Further, inhibition of PAG
microglia with the selective TLR4 antagonist (+)-naloxone significantly potentiates morphine
analgesia in females but not males, and thus abolishes the sex difference in opioid response
(Doyle et al., 2017). These results suggest that PAG microglia are innately different in males and
females in terms of their morphological state and implicate TLR4 in the attenuated response to
morphine observed in females.
Experiments on possible sex differences in the inflammatory processes resulting from
persistent inflammatory pain, the receptor-binding properties of exogenous opioids, as well as
sex differences in the downstream activity of MOR, will provide a more detailed model of the
mechanisms underlying sex differences in opioid analgesia. Moreover, continued study of the
origins of these sex differences (be they hormonal, autosomal, or epigenetic) will provide novel
information on the mechanisms underlying the phenotypical differences between males and
females. The present studies represent the first known analyses of the impact of biological sex on
PAG opioid signaling in the presence of chronic pain that use both adult and aged animals.
1.4

PAG neuronal MOR signaling
The PAG’s role in descending pain modulation was first identified by Reynolds (1969)

who reported that electrical stimulation of the rat PAG was sufficient to produce potent
analgesia, such that abdominal surgery was performed without anesthesia or additional
pharmacological intervention. Interestingly, experimental rats still oriented to non-painful
stimuli, indicating that PAG stimulation selectively inhibits noxious stimulation (Reynolds,
1969). Analgesia produced by PAG stimulation is MOR-dependent, as intra-PAG injection of the
MOR antagonist (-)-naloxone attenuates the analgesia produced by PAG stimulation (Akil et al.,
1976). Further, direct administration of MOR agonists into the PAG promotes potent analgesia
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(Satoh et al., 1983; Jensen & Yaksh, 1986; Bodnar et al., 1988). Analgesia produced by PAG
MOR agonism, particularly morphine analgesia, is attenuated by PAG MOR antagonism via (-)naloxone (Ma & Han, 1991; Y. Zhang et al., 1998) and by lesions of MOR+ PAG neurons in
male rats (Loyd et al., 2008).
Opioid binding at vlPAG MOR+ GABAergic interneurons induces a downstream
signaling cascade causing neuronal hyperpolarization which limits GABA output, thus
disinhibiting neurons projecting to the RVM (H. Wang & Wessendorf, 2002; Al-Hasani &
Bruchas, 2011; Samineni et al., 2017); however, the mechanism(s) by which PAG MOR
activation hyperpolarizes GABAergic neurons depends on the neuronal location of MOR
(presynaptic, postsynaptic) (Lueptow et al., 2018). Opioid agonist binding to postsynaptic MOR
elicits direct neuronal hyperpolarization via activation of the Gα subunit of the coupled Gprotein. This results in the opening of G-protein inwardly rectifying potassium (GIRK) channels,
and the subsequent potassium efflux induces neuronal hyperpolarization (North & Williams,
1983; Pan et al., 2005). Concurrently with GIRK channel opening, the Gα and Gβγ subunits of
the coupled inhibitory Gi/o proteins inhibit the enzymatic activity of downstream effector
adenylyl cyclase (AC). G-protein-mediated AC inhibition limits the conversion of adenosine
triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP) (van
Keulen & Rothlisberger, 2017).
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Alternatively, opioid binding at presynaptic
MOR inhibits the release of GABA directly at the
synapse via activation of the Gβγ subunits of the
coupled G-protein, which subsequently inhibit
voltage-gated calcium channels and activate voltagegated potassium channels to limit neurotransmitter
release (Wilding et al., 1995; Vaughan et al., 1997;
Connor & Christie, 1999; Williams et al., 2001)
(Figure 1.2).
The present studies assess the impact of
advanced age on PAG MOR agonist binding, Gprotein activation, and cAMP inhibition; these
processes are all critical for opioid signaling and
subsequent pain inhibition. These studies also assess
how advanced age impacts the regulation of PAG
MOR signaling by measuring MOR

Figure 1.2 MOR Signaling within the PAG
Pre- and post- synaptic MOR signaling in
the PAG hyperpolarizes GABAergic neurons and
disinhibits RVM output neurons. From Lueptow et
al., 2018.

phosphorylation and expression of Regulator of Gprotein signaling proteins within the PAG.
1.4.1

MOR Agonist Binding

Opioid binding at MOR is critical for the promotion of analgesia (Roeckel et al., 2016;
Ricarte et al., 2021). The magnitude of analgesia produced is dependent on the expression of
functional MORs on the cell membrane surface as well as the affinity membrane-bound MORs
exhibit for the agonist (Trescot, 2008). Receptor binding assays using a radioactive ligand are a
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widely used tool for quantifying a ligand’s efficacy to bind to its receptor (J. R. Traynor &
Nahorski, 1995; Márki et al., 1999).This assay analyzes the interaction between a receptor and its
ligand by providing a measure of total available receptor (Bmax), along with a measure of a
ligand’s affinity for its receptor (Kd). The ratio of these values form the ligand-receptor binding
potential, an index for determining the likelihood of an agonist to elicit a receptor-mediated
response (Noël et al., 2001; Maguire et al., 2012).
Previous studies suggest that advanced age is concomitant with reduced receptor affinity;
elderly humans exhibit reduced B-adrenergic receptor affinity (Feldman et al., 1984), and aging
rats exhibit decreased affinity of cardiac muscarinic receptors (Baker et al., 1985). Indeed, in the
spinal cord, male Fischer-344 rats aged 25 months exhibit significantly increased DAMGO Kd
values compared to males aged 6 months, indicating reduced affinity of the receptor for the
ligand in advanced age (Hoskins et al., 1998). This age-induced reduction in MOR affinity
suggests a mechanism whereby MOR signaling is attenuated in advanced age, resulting in a
reduction in the therapeutic efficacy of opioids in the elderly. The present studies assess how
advanced age impacts MOR affinity and availability in the vlPAG in both male and female rats
in the presence of chronic inflammatory pain.
1.4.2

G-protein activation

MORs primarily couple with G-proteins of the inhibitory type to carry out downstream
neuronal hyperpolarization, primarily coupling the G-alpha-iota/o (Gαi/o) class of adenylyl
cyclase inhibitory Gα proteins. In the absence of a bound agonist (i.e., resting state), the 3
subunits of the G-protein form a heterotrimeric Gαβγ complex that couples to the MOR receptor.
In this formation, the Gα subunit is bound to the inactive guanosine diphosphate (GDP). When
an opioid agonist (such as morphine) binds to the extracellular N-terminus domain of MOR, the
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G-protein complex uncouples from MOR. This binding promotes the dissociation of GDP from
the Gα subunit and the subsequent binding of guanosine triphosphate (GTP). The binding of
GTP to Gα catalyzes the subunit, resulting in the separation of Gα from the Gβγ heterodimer
(Fig 1.3). The dissociated Gα-GTP and Gβγ complexes interact with unique downstream
intracellular signaling pathways: Gαi/o inhibits AC, limiting the conversion of ATP into cAMP,
and Gβγ inhibits calcium channels, limiting neurotransmitter release. G-protein intracellular
signaling is terminated by the action of the Gα subunit’s intrinsic GTPase, which hydrolyzes
GTP to GDP (Ross & Wilkie, 2000; Hollinger & Hepler, 2002).
The present studies assess how advanced age affects opioid-induced G-protein activation
in the vlPAG in the presence of chronic pain. MOR coupling to Gαi/o increases throughout
postnatal development and stabilizes in adulthood (Talbot et al., 2005), and is then
downregulated throughout the brain in advanced age, most notably in the prefrontal cortex
(Young et al., 1991; Alemany et al., 2007; de Oliveira et al., 2019), with estimates of reduced
expression as high as 65% in the frontal cortex, hippocampus, substantia nigra, and striatum (de
Oliveira et al., 2019).
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Figure 1.3 G-protein activation and signaling
MOR binding induces G-protein activation and dissociation by GTP and promotes second
messenger signaling

1.4.3

cAMP inhibition

A primary target of MOR downstream signaling by Gαi/o is the effector adenylyl cyclase
(AC). AC enzymatically converts adenosine triphosphate (ATP) to the excitatory second
messenger cyclic adenosine monophosphate (cAMP). MOR initiation of Gαi/o signaling inhibits
AC, thereby reducing cAMP expression (Santhappan et al., 2015)(Fig 1.3). Inhibition of cAMP
limits the activation of cAMP-dependent protein kinase A (PKA), thus promoting inhibitory
MOR signaling by limiting neuronal depolarization (Connor & Christie, 1999).
Several studies have assessed the impact of advanced age on cAMP production and
signaling in the brain. Decreased cAMP expression has been reported in the cortex, thalamus,
and midbrain of aged rats (Puri & Volicer, 1981; Titus et al., 2013; Kelly, 2018). Alternatively,
age-dependent increases in cAMP activity, (assessed by measurement of cyclic AMP
phosphodiesterase) have been reported in the rodent basal forebrain and hypothalamus
(Stancheva & Alova, 1991; Asanuma et al., 1996). In addition to region-specific decreases in
cAMP, widespread reductions in ATP, the precursor responsible for cAMP production, have

17
been reported in aged rodents (Błaszczyk, 2020). Further, AC binding shows age-related
dysregulation, wherein the binding of forskolin, a nonspecific AC activator, is reduced within the
cerebral cortex and hippocampus of 24-month-old rats (Araki et al., 1995).
To date, it is not known how advanced age (or sex) impacts cAMP expression in the
vlPAG, nor whether vlPAG cAMP is altered as a function of chronic inflammatory pain. The
present experiments assess whether the efficiency of opioid-induced cAMP inhibition within the
PAG is impacted by advanced age, and thus determine whether advanced age alters opioid
signaling via a cAMP-dependent mechanism.
1.4.4

MOR phosphorylation

The use of opioids for the management of pain is associated with the development of
negative side effects including sedation, gastrointestinal immotility and respiratory depression
(Koehl et al., 2018). These side effects are thought to be driven, in part, by the activity of a
family of proteins called arrestins, particularly that of Beta-arrestin-2 (β-arrestin 2). β-arrestin 2
is an intracellular protein that acts to desensitize GPCRs. Opioid binding is thought to promote
MOR phosphorylation at serine and threonine residues in the receptor carboxyl-terminal via Gprotein receptor kinase 2 (GRK2) and protein kinase C (PKC), promoting the recruitment of βarrestin 2, and subsequent clathrin-mediated receptor internalization (Lohse et al., 1992; DiCello
et al., 2019). Thus, receptor phosphorylation limits agonist binding and attenuates opioid
signaling (L. Zhang et al., 1996; Yu et al., 1997; Groer et al., 2011). In addition to desensitizing
the receptor via internalization, β-arrestin binding to phosphorylated MOR is thought to promote
the uncoupling of MOR from associated G-proteins, thus reducing the efficacy of MORmediated analgesia (Ferguson et al., 1996; Al-Hasani & Bruchas, 2011). Although the majority
of studies assess agonist-induced receptor phosphorylation, basal phosphorylation (i.e., in the
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absence of an agonist) also plays an important role in the maintenance of cell signaling (Rankin
& Sibley, 2010). Basal, or constituent, receptor phosphorylation via GRK2 and PKC have also
been shown to desensitize MOR signaling, suggesting that differences in opioid efficacy may
result from differences in basal MOR phosphorylation in the PAG (Lemel et al., 2020). Previous
studies have reported changes in receptor internalization (and thereby receptor phosphorylation)
as a function of advanced age (L. Liu et al., 1998; Blanpied et al., 2003).
1.4.5

Regulator of G-protein Signaling (RGS) proteins

G-protein-dependent signaling pathways are tightly regulated to maintain receptor
responsiveness to external stimuli. Regulators of G-Protein Signaling (RGS) proteins are a
family of cellular proteins that primarily act to negatively modulate G-protein signaling by
interacting with the GTP – GDP cycle. RGS proteins regulate G proteins by acting as GTPaseaccelerating proteins (GAPs), whereby they enhance the intrinsic GTPase activity of Gα
subunits, thus accelerating GTP hydrolysis. RGS proteins increase the intrinsic rate of GTP
hydrolysis up to 100-fold, thereby aiding the hydrolyzation of the active GTP back into GDP and
terminating downstream signaling (De Vries et al., 2000; Roman & Traynor, 2011; Gerber et al.,
2016).
Several members of the RGS family have been reported to regulate G-protein-mediated
opioid signaling (Ross & Wilkie, 2000; J. Traynor, 2012; Senese et al., 2020). Indeed, functional
studies suggest that two RGS proteins in particular, RGS4 and RGS9-2, are key players in opioid
receptor signaling (Xie & Palmer, 2005). RGS4 is expressed in many structures involved in pain
transmission, including the dorsal horn of the spinal cord and the PAG (Avrampou et al., 2019).
In-vitro studies in human embryonic kidney cells reported that overexpression of RGS4
attenuates morphine-induced adenylyl cyclase inhibition (Garnier et al., 2003). Further,
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intrathecal inhibition of RGS4 reduced formalin nociception and enhanced DAMGO-mediated
analgesia in male mice (Yoon et al., 2015). RGS9-2 is also expressed in the spinal cord and
PAG, and its role in opioid analgesia has also been examined in rodent studies. Morphine
analgesia in warm-water tail flick assays is potentiated in RGS9- global knockdown mice
(Garzón et al., 2001). Additionally, morphine analgesia in both tail flick and hot plate assays is
potentiated in RGS9- global knockout mice compared to controls (Zachariou et al., 2003).
Several studies have linked advanced age and RGS expression, suggesting that changes
in the brain that develop with age-related diseases (Parkinson’s Disorder and Alzheimer’s
disease) are dependent on RGS4 and RGS9-2 (Tekumalla et al., 2001; Muma et al., 2003). Using
quantitative immunohistochemistry, Kim et al. (2005) reported higher RGS9-2 protein levels in
the PAG of 1-year compared to 3-week-old male rats (Kim et al., 2005). Further, previous
research suggests that chronic pain downregulates the signaling of G-proteins bound to MOR
(Psifogeorgou et al., 2007; Avrampou et al., 2019). However, it is not known how advanced age
and biological sex impact RGS levels in the PAG in the presence of chronic pain.

Figure 1.4 Regulator of G-protein signaling (RGS) proteins
RGS proteins promote the acceleration of GTPase, thus negatively modulating G-protein signaling
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1.5

Aims
Preliminary studies in our laboratory assessed morphine anti-hyperalgesia 24 hours

following intraplantar CFA. Adult and aged, male and female Sprague Dawley rats were
administered subcutaneous morphine using a cumulative dosing paradigm. Withdrawal response
to a noxious thermal stimulus were assessed at dosing intervals to determine median effective
concentration of morphine (EC50). These preliminary experiments show that aged males and
females of both ages exhibit increased EC50 values compared to their adult male counterparts,
indicating reduced morphine potency in aged males and females. In a second set of preliminary
experiments, morphine and DAMGO were administered to adult and aged males via intra-PAG
injection 24 hours post-CFA. Aged males exhibited reduced anti-hyperalgesic potency of both
intra-PAG morphine and DAMGO, suggesting that age differences in opioid signaling in the
PAG contribute to reduced morphine potency. Thus, the present studies were designed to test the
hypothesis that advanced age and biological sex impact morphine analgesic potency by altering
opioid signaling in the midbrain periaqueductal gray. Chronic pain is a debilitating disease that is
pervasive in the aged population, and there exists a critical gap in research regarding adequate
dosing of opioids for the management of chronic pain in the elderly.
Our objectives are to test cellular and pharmacological activities integral to the generation
of opioid analgesia in adult and aged, male and female rats in the presence of persistent
inflammatory pain. We use a clinically relevant model of the persistent pain experienced by
humans for which morphine treatment is indicated. This work characterizes age- and sex-induced
changes in the mechanisms by which opioids induce analgesia, identifying potential targets for
the enhancement of morphine analgesia in aged individuals.
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Aim 1 – Assess the impact of age and sex on sensitivity to peripheral inflammatory
pain and the impact of advanced and sex on morphine anti-hyperalgesic potency.
Preclinical studies indicate that aged rats require higher doses of morphine for adequate
analgesia compared to adults. We test the hypothesis that advanced age attenuates the
modulation of chronic pain but not the nociceptive response to painful stimuli by assessing
sensitivity to peripheral thermal pain and assessing morphine anti-hyperalgesia in the presence of
chronic pain. Intraplantar injection of CFA is used to induce chronic inflammatory pain to test if
age impacts the anti-hyperalgesic potency of morphine in male and female rats. Morphine
effective concentrations (EC50s) are determined for opioid potency using a cumulative dosing
paradigm and paw thermal stimulation. These experiments performed on adult/aged, male/female
rats provide behavioral evidence that opioid signaling is altered in aged rodents.
Aim 2 - Assess the impact of advanced age and sex on mu opioid receptor mRNA
and protein expression and binding in the ventrolateral periaqueductal gray. Our lab has
previously shown that administration of MOR antagonists into the PAG significantly attenuates
the analgesic effects of systemic morphine, suggesting that functional MOR in the vlPAG is
critical for opioid analgesia. Given the attenuation in morphine action observed in aged rats, the
present studies test the hypothesis that the attenuated response to morphine observed in aged
male rats is due to decreased MOR expression and binding in the vlPAG compared to young
adults. We assess vlPAG MOR in adult/aged, male/female rats using several complementary
techniques. MOR mRNA and protein levels are assessed using RNAscope and
immunohistochemistry (IHC), respectively. These studies establish anatomical differences but do
not address potential changes in the ability of the receptor to bind ligand. Thus, we also use
autoradiography to assess vlPAG MOR binding. Together, these studies provide anatomical and
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functional evidence of the impact of age, sex, and persistent pain on opioid signaling in the
vlPAG.
Aim 3 - Identify age- and sex-induced differences in vlPAG MOR affinity,
availability, G-protein activation, and cAMP inhibition. Agonist binding vlPAG MOR is
critical for opioid analgesia. Binding induces the activation of coupled G-proteins that promote
second messenger signaling cascades and ultimately inhibit afferent pain signals, notably via
inhibition of cAMP production. The present studies examine the hypothesis that the attenuated
response to morphine observed in aged rats is due to reductions in vlPAG MOR affinity and
availability, dampened opioid-induced G-protein activation, and reduced cAMP inhibition. In the
present studies, we assess MOR affinity and availability using radioligand-binding assays to
generate Kd (receptor affinity) and Bmax (receptor availability) values. We assess G-protein
activation using the GTPγS assay to generate G-protein efficacy and potency values. And we
assess opioid-induced cAMP inhibition using the cAMP assay. These data derived from
adult/aged, male/female rats provide novel evidence on the impact of advanced age and sex on
vlPAG MOR signaling.
Aim 4 - Determine if vlPAG MOR phosphorylation state or RGS expression are
altered by advanced age and biological sex. MOR signaling is modulated by receptor
phosphorylation, which limits agonist binding and recruits arrestin proteins, downregulating
opioid signaling. Further, regulator of G-protein signaling (RGS) proteins attenuate G-protein
activity by accelerating the hydrolysis of GTP. We test the hypothesis that the attenuated
response to morphine observed in aged male rats is due to heightened MOR phosphorylation and
greater expression of RGS proteins in the aged vlPAG. We assess MOR phosphorylation in
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adult/aged, male/female rats using Western blot detection of immunoprecipitated proteins, and
assess RGS mRNA using single-molecule fluorescent in situ hybridization.
The outcome of this work is a profile of the impact of advanced age and biological sex on
opioid analgesic potency, namely on opioid signaling in the vlPAG. The present studies establish
the impact of advanced age and biological sex on morphine anti-hyperalgesia, vlPAG MOR
expression and binding, MOR signaling, and opioid signaling regulation.
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2.1

Abstract
The present study investigated the impact of advanced age on morphine modulation of

persistent inflammatory pain in male and female rats. The impact of age, sex, and pain on μopioid receptor (MOR) expression and binding in the ventrolateral periaqueductal gray (vlPAG)
was also examined using immunohistochemistry and receptor autoradiography. Intraplantar
administration of complete Freund's adjuvant induced comparable levels of edema and
hyperalgesia in adult (2–3 mos) and aged (16–18 mos) male and female rats. Morphine potency
was highest in adult males, with a greater than two-fold increase in morphine EC50 observed in
adult versus aged males (3.83 mg/kg vs. 10.16 mg/kg). Adult and aged female rats also exhibited
significantly higher EC50 values (7.76 mg/kg and 8.74 mg/kg, respectively) than adult males. The
upward shift in EC50 from adult to aged males was paralleled by a reduction in vlPAG MOR
expression and binding. The observed age-related reductions in morphine potency and vlPAG
MOR expression and binding have significant implications in pain management in the aged
population.
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2.2

Introduction
The US population is rapidly aging, and in the coming decade, over 20% of US citizens

will be 65 years of age or older (Frieden, 2016.). It is estimated that over 50% of these
individuals will experience persistent and/or severe pain, including pain associated with arthritis,
cancer, diabetes mellitus, and cardiovascular disease (Dahlhamer, 2018; Domenichiello &
Ramsden, 2019). Persistent pain in the elderly typically involves multiple sites and is comorbid
with a variety of other conditions, resulting in depression, sleep disruption, cognitive
impairment, and decreased socialization. Together, these factors potentially decrease quality of
life and increase the risk of early death (Patel et al., 2013; Makris et al., 2014; Reid et al., 2015;
Domenichiello & Ramsden, 2019). Although opioids, including morphine and fentanyl, are the
most potent and commonly prescribed analgesics for chronic pain management, pain in the
elderly is typically undermanaged or ignored altogether (Pergolizzi et al., 2008). Several factors
contribute to the undermanagement of pain in the elderly, including under-reporting of pain
intensity by the patient, physician reluctance to prescribe opioids due to fears of adverse side
effects including cognitive impairment and respiratory depression, and misconceptions on the
part of the patient and physician regarding tolerance and addiction (Cavalieri, 2005; Saunders et
al., 2010; Miaskowski, 2011; Miaskowski et al., 2011; Schiltenwolf et al., 2014; Naples et al.,
2016; Prostran et al., 2016)

Although opioids for chronic pain management in the elderly are finally beginning to
increase (Pokela et al., 2010; Lapane et al., 2013), there remains a dearth of information
regarding the suitable dosing regimen (Campbell et al., 2010). Clinical studies examining opioid
potency in the elderly are inconsistent, with reports of increased, decreased, or equivalent
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sensitivity compared with adults (Kaiko, 1980; Gagliese & Katz, 2003; Papaleontiou et al., 2010;
Prostran et al., 2016). Several factors likely contribute to these disparate results. First, although
opioids are prescribed for the alleviation of severe and persistent pain, most of these studies were
conducted in elderly patients experiencing acute pain. The presence of comorbid conditions such
as diabetes and high blood pressure, and the use of concomitant medications, may also either
augment or potentiate morphine's analgesic effects. These studies also typically fail to include
sex as a biological variable, either not reporting it or focusing exclusively on males (Gagliese &
Katz, 2003; Aubrun et al., 2005; Lautenbacher, 2012), leaving the impact of age on opioid
modulation of pain in women largely unknown. Sex and age differences in the likelihood of selfreporting pain in a clinical setting, along with the subjective nature of pain, further contribute to
the contradictory findings regarding effective dosing in the aged population (B. R. Ferrell et al.,
1991; Reddy et al., 2012; Dampier et al., 2013).

Preclinical studies in rodents have also failed to provide insight regarding the impact of
advanced age on opioid modulation of pain. First, very few studies have been conducted, and
similar to their clinical counterparts, these studies report increased, decreased, and no change in
opioid potency as a function of age (Chan & Lai, 1982; Kramer & Bodnar, 1986; Gagliese &
Melzack, 2000). These studies also suffer from the same shortfalls identified for clinical studies,
including acute rather than chronic pain assays (typically tail-flick or hot plate) and use of male
subjects exclusively (Chan & Lai, 1982; Kavaliers et al., 1983; Smith & Gray, 2001; Jourdan et
al., 2002). Therefore, a clear picture regarding the impact of advanced age on opioid potency has
yet to emerge.
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The endogenous descending analgesia circuit, consisting of the midbrain periaqueductal
gray (PAG) and its descending projections to the rostral ventromedial medulla and dorsal horn of
the spinal cord, is a critical neural circuit for exogenous pain modulation (Basbaum et al., 1976,
1978; Basbaum & Fields, 1979; Behbehani & Fields, 1979; Morgan et al., 1992, 2006). The
ventrolateral PAG (vlPAG) contains a large population of mu opioid receptor positive (MOR+)
neurons,- the preferred receptor for morphine (Martin, 1963; Wolozin & Pasternak, 1981), and
direct administration of MOR agonists into the PAG produces potent analgesia (Satoh et al.,
1983; Jensen & Yaksh, 1986; Bodnar et al., 1988). Conversely, direct administration of MOR
antagonists into the PAG, or lesions of PAG MOR, significantly attenuate the analgesic effect of
systemic morphine (Wilcox et al., 1979; Ma & Han, 1991; Y. Zhang et al., 1998; Loyd et al.,
2008). Despite high rates of chronic pain among the elderly, and reported age differences in
morphine potency, surprisingly little is known regarding how advanced age influences the
distribution and function of MOR in the PAG.

Here, we present a series of experiments delineating the impact of advanced age on
opioid analgesia and the expression and binding of MOR in the vlPAG of the male and female
rat. These studies provide the first data on age-mediated changes in the cellular and molecular
processes of a central neural circuit governing pain and opioid analgesia in a persistent
inflammatory pain model.

2.3

Materials and Methods
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2.3.1

Experimental subjects

Adult (2–3 mos) and aged (16–18 mos) male and regularly cycling female SAS Sprague
Dawley rats were used in these experiments (Charles River Laboratories, Boston, MA). Rats
were co-housed in same-sex pairs on a 12:12 hours light/dark cycle (lights on at 08:00 am).
Access to food and water was ad libitum throughout the experiment, except during testing. All
studies were approved by the Institutional Animal Care and Use Committee at Georgia State
University and performed in compliance with Ethical Issues of the International Association for
the Study of Pain and National Institutes of Health. All efforts were made to reduce the number
of rats used in these experiments and to minimize pain and suffering.

2.3.2

Vaginal cytology

Beginning ten days before testing, vaginal lavages were performed daily on adult and
aged female rats to confirm that all rats were cycling regularly and to keep daily records of the
stage of estrus. Proestrus was identified as a predominance of nucleated epithelial cells, and
estrus was identified as a predominance of cornified epithelial cells. Diestrus 1 was differentiated
from diestrus 2 by the presence of leukocytes. Rats that appeared between phases were noted as
being in the more advanced stage (Loyd et al., 2007).

2.3.3

Behavioral testing

Adult (2–3 mos) and aged (16–18 mos), male and female rats were used in the behavioral
studies examining the impact of age and sex on morphine potency (n = 6–10/group; N = 32). As
previously described, thermal nociception was assessed using the paw thermal stimulator (Univ.
California San Diego) (Hargreaves et al., 1988; X. Wang et al., 2006). Briefly, the rat was placed in a
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clear plexiglass box resting on an elevated glass plate maintained at 30 °C. A timer was initiated
as a radiant beam of light was positioned under the hind paw, and the time point at which the rat
retracted its paw in response to the thermal stimulus was electronically recorded as the paw
withdrawal latency (PWL) in seconds (s). A maximal PWL of 20s was used to prevent tissue
damage due to the repeated application of a noxious thermal stimulus. Rats were acclimated to
the testing apparatus 30–60 minutes before the start of the experiment on the day of testing. All
behavioral testing took place between 08:00 am and 12:00 pm (lights on at 08:00 am). The
maximum temperature of the thermal stimulus was recorded before and after each trial to
maintain consistent recordings between groups and did not exceed a range of 60 °C–65 °C
throughout the experiments. All testing was conducted blind with respect to group assignment.

2.3.4

Inflammatory hyperalgesia and edema

After baseline PWL determination, persistent inflammation was induced by injection of
complete Freund's adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 μL), suspended in
an oil/saline (1:1) emulsion, into the plantar surface of the right hind paw. Paw diameters were
determined using calibrated calipers applied midpoint across the plantar surface of both hind
paws before and after induction of inflammation.

2.3.5

Morphine administration

Twenty-four hours after CFA administration, 32 rats (n = 7–9 per group) were
administered morphine using a cumulative dosing paradigm as previously described (Loyd et al.,
2008). Briefly, rats received subcutaneous injections of morphine sulfate every 20 minutes (1.8,
1.4, 2.4, 2.4, 2.0, and 8.0), resulting in the following doses: 1.8, 3.2, 5.6, 8.0, 10.0, and 18.0
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mg/kg (s.c; NIDA; Bethesda, MD, USA). PWLs were determined 15 minutes after each
administration. Morphine sulfate was prepared in a saline vehicle within 24 hours of
administration.

2.3.6

Perfusion fixation

Immunohistochemical localization of MOR was determined in a separate cohort of adult
and aged male and female rats. To determine the impact of persistent inflammatory pain on
MOR expression, a subset of rats in each treatment group received an intraplantar injection of
CFA 24–72 hours before perfusion (total of 8 treatment groups; n = 5–8; N = 45). Rats were
given a lethal dose of Euthanasol (i.p.) and transcardially perfused with 200–250 mL of 0.9%
sodium chloride containing 2% sodium nitrite as a vasodilator to remove blood from the brain,
followed by 300–400 mL of 4% paraformaldehyde in 0.1 M phosphate as a fixative. Immediately
after perfusion, brains were removed and stored in 4% paraformaldehyde solution. After 24
hours, brains were placed in a 30% sucrose solution and stored at 4 °C for at least one week
before sectioning. Brains were cut coronally into 25-μm sections with a Leica 2000R freezing
microtome and stored free-floating in cryoprotectant antifreeze solution (Watson et al., 1986) at
−20 °C until immunohistochemical processing.
2.3.7

Immunohistochemistry

Coronal sections from the midbrain were removed from cryoprotectant and processed for
MOR immunoreactivity, as previously described (Loyd et al., 2008). Briefly, sections were
rinsed extensively in potassium phosphate–buffered saline (KPBS) to remove the cryoprotectant
solution. After rinsing in KPBS, sections were incubated in a blocking solution of 5% Normal
Donkey Serum in KPBS containing 0.5% Triton X-100 for 1 hour at room temperature. For
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immunofluorescence, the tissue was incubated in an antibody solution of rabbit anti-MOR
(specifically targeting the extracellular N-terminus of the receptor; Alomone Labs, Jerusalem,
Israel; 1:1000) in KPBS containing 1.0% Triton X-100 for 1 hour at room temperature followed
by 48h at 4 °C. After rinsing in KPBS, sections were incubated in a Donkey anti-Rabbit 488
(1:200) solution for 2h at room temperature. Tissues were then rinsed using KPBS and mounted
using SlowFade Diamond Antifade Mountant (Invitrogen). Images were processed on Zeiss
LSM 700 Confocal Microscope at 40x.

To quantify neuronal number within the vlPAG, a second set of sections were stained
using mouse anti-NeuN (Millipore Bioscience Research Reagents; 1:50,000). A third set of
sections containing the inferior colliculus (IC; anatomical control) and PAG was stained using
rabbit anti-MOR (Alomone Labs; 1:7500) and visualized using nickel sulfate intensified 3,3′diaminobenzidine (Ni-DAB). After incubation in primary antibody solution as described
previously, the tissue was rinsed with KPBS, incubated for 1h in biotinylated goat anti-mouse
IgG or donkey anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA), rinsed again
with KPBS, and then incubated for 1 hour in avidin-biotin-peroxidase complex (1:10; ABC Elite
Kit, Vector Laboratories). After rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), NeuN
and MOR immunoreactivity were visualized as a black reaction product using Ni-DAB
containing 0.08% hydrogen peroxide in KPBS (pH 7.4). After incubating for 15–30 minutes, the
reaction was terminated by rinsing in sodium acetate buffer. Tissue sections were mounted out of
KPBS onto gelatin-subbed slides, air-dried overnight, dehydrated in a series of graded alcohols,
cleared in xylene, and coverslipped using permount.
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2.3.8

Anatomical data analysis and presentation

Fluorescent images were captured on Zeiss LSM 700 confocal microscope at 40x, and
MOR intensity (signal intensity/signal volume) was calculated using Imaris software. MOR
intensity values were determined for the left and right ventrolateral subdivision of each PAG
image from 2 representative levels of the mid-caudal PAG (Bregma −7.74 and −8.00) and were
averaged for each slice. Photomicrographs from Ni-DAB–stained sections were generated using
a Sensys digital camera attached to a Nikon Eclipse E800 microscope. Images were captured
with IP Spectrum software and densitometry of labeling assessed in ImageJ. Densitometry
measurements were conducted bilaterally as separate images of the left and right side and
averaged. As there was no significant effect of rostrocaudal level in the analyses, we then
averaged the values from both levels to derive an average value per animal. Intensity and
densitometry values are expressed as the mean ± standard error of the mean (SEM). Previous
data have shown that there are no sex differences in total area (mm2) of the PAG between male
and female Sprague Dawley rats (Loyd & Murphy, 2006). All images were collected and
analyzed by an experimenter blinded to the experimental condition.

2.3.9

Receptor autoradiography

To determine the impact of age, sex, and pain on vlPAG MOR binding, a separate cohort
of adult and aged, male and female, and handled and CFA treated rats (total of 8 treatment
groups; n = 6; N = 48) were used for receptor autoradiography. Rats were restrained using
DecapiCones and decapitated. Brains were removed rapidly, flash frozen in 2-methyl butane on
dry ice, and stored at −80 °C. Frozen tissue was sectioned in a 1:6 series of 20 μm coronal
sections at –20 °C with a Leica CM3050S cryostat. Sections were immediately mounted onto
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Superfrost slides (20 °C) and stored at −80 °C until the time of the assay. Tissue was processed
for autoradiography as previously described (Loyd et al., 2008; LaPrairie & Murphy, 2009).
Briefly, sections were allowed to thaw to room temperature and fixed in 0.1% paraformaldehyde
followed by rinses in 50 mM Tris buffer, pH 7.4. Slides were then placed in a tracer buffer
containing tritiated DAMGO (100 nM; American Radiolabeled Chemicals) for 60 minutes
followed by a series of rinses in 50 mM Tris buffer, pH 7.4, containing MgCl2. After a final dip
in cold dH20, tissue was allowed to dry at room temp. Slides were then apposed to FujiFilm
imaging plates along with [3H]-microscale standards (PerkinElmer/NEN, MA, USA) for six
weeks. Image plates were processed with a FujiFilm BAS 5000. Autoradiographic [3H]-receptor
binding was quantified from the images using Scion Image software. [3H]-standards were used
to convert uncalibrated optical density to disintegrations per minute (DPM). For analysis, DPM
values were determined for the left and right ventrolateral subdivision of each PAG image from
2 representative levels of the mid-caudal PAG (Bregma –7.74 and –8.00) and averaged for each
animal.

2.3.10 Statistical analysis and data presentation
All values are reported as mean ± SEM. For behavioral data analysis, data are expressed
as either raw PWLs or percent maximal possible effect (%), defined as [(PWL–CFA
baseline)/(maximal PWL–CFA baseline)] × 100. Significant main effects of sex, age, and
treatment were assessed using ANOVA or repeated measures ANOVA; p < 0.05 was considered
statistically significant. Tukey's post hoc tests were conducted to determine significant mean
differences between groups that were a priori specified. Our behavioral data suggested that
morphine was less potent in aged males and females, leading us to hypothesize that MOR
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expression and binding were reduced in the vlPAG of aged rats as well as females; thus, onetailed post hoc tests were used for immunohistochemistry and autoradiography. All data were
analyzed for identification of outliers using the ROUT method in GraphPad Prism, and data
points meeting the criteria were removed from analysis. Anatomical data are expressed either as
percent area covered for Ni-DAB immunohistochemistry (IHC), intensity (signal intensity/signal
volume) for fluorescent IHC, or DPM for autoradiography data. For data presentation, a
representative animal from each experimental group was selected, and photomicrographs
generated using a confocal microscope. Images were captured and processed with Imaris
software (IHC) or processed with Scion Image (autoradiography). Alterations to the images were
strictly limited to the enhancement of brightness and contrast.
2.4

Results
2.4.1

No impact of advanced age or sex on basal thermal nociception or the
magnitude of CFA-induced hyperalgesia

To assess the impact of age and sex on baseline thermal nociception, paw withdrawal
latencies (PWLs) in response to a noxious thermal stimulus were determined (Hargreaves et al.,
1988). No significant impact of age [F(1,28) = 3.384, p = 0.078] or sex [F(1,28) = 1.362, p = 0.253]
was noted for baseline PWL (Fig. 1A). Similarly, no significant effect of age [F(1,33) = 2.323, p =
0.137] or sex [F(1,33) = 2.533, p = 0.121] on the magnitude of CFA-induced hyperalgesia was
observed (Fig. 1B). In all 4 groups, CFA reduced PWLs from 8.26s to 3.86s, an average %
change in PWLs of –53.4% (Fig. 1C). The inflammatory insult induced by CFA injection
resulted in comparable inflammation in all experimental groups, with no significant impact of
age [F(1,40) = 2.171, p = 0.149] or sex [F(1,40) = 0.491, p = 0.487]. In all 4 groups, CFA increased
paw diameter by an average % change of 168.2% (Fig. 1D).
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Figure 2.1 Basal thermal nociception and CFA-induced hyperalgesia
No impact of age or sex was observed for basal thermal nociception (A) or post-CFA PWLs (B). Similarly,
no age or sex difference in the magnitude of CFA-induced hyperalgesia (C) or CFA-induced edema (D). ns, not
significant calculated by two-way ANOVA. Graphs indicate mean ± SEM.

2.4.2

Age and sex differences in morphine anti-hyperalgesia

We next determined the impact of age and sex on morphine potency using a cumulative
dosing paradigm to derive EC50 (Fig. 2A). Our analysis of opioid potency indicated a significant
dose × age interaction, [F(6, 174) = 6.81, p < 0.0001], a significant dose × sex interaction [F(6, 174) =
2.65, p = 0.0173], and a significant age × sex interaction [F(1, 29) = 8.86, p = 0.0058]. Further
analysis of EC50 values from each animal indicated a significant age × sex interaction [F(1, 28) =
11.42, p = 0.0022] (Fig. 2B). Aged male rats were less sensitive to morphine than their adult
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counterparts, with a two-fold increase in EC50 compared with adult males (EC50 = 10.16 mg/kg
vs. EC50 = 3.83; p = 0.0002; Fig. 2C). Adult and aged females were also less sensitive to
morphine than adult males (EC50 = 7.76 mg/kg and 8.74 mg/kg vs. EC50 = 3.83 mg/kg; p =
0.0076 and p = 0.0103, respectively). Females showed no age differences, with similar EC50
values observed for adult and aged rats (EC50 = 7.76 mg/kg vs. EC50 = 8.74).

Figure 2.2 Morphine anti-hyperalgesia
Morphine dose response curve after cumulative administration (A). EC 50 values were generated from
nonlinear regression analysis (B). Adult males exhibit lower morphine EC 50 values than females and aged males.
(C) Data presented in milligrams of morphine per kilogram of body weight. ∗Significant differences between
adult male and adult female, adult male and aged male, and adult male and aged female. p < 0.05 calculated by
Tukey's post hoc test. Graphs indicate mean ± SEM.

2.4.3

Impact of advanced age, sex, and chronic pain on MOR expression in the
midbrain vlPAG

We next sought to determine if age and sex differences in mu opioid receptor levels in the
vlPAG contributed to our observed behavioral differences. An example of MOR immunostaining
in the vlPAG is shown in Fig. 3A. Our analysis indicated a significant impact of age on vlPAG
MOR expression, with aged rats expressing a loss in vlPAG MOR density compared with adults
[F(1,37) = 9.933, p = 0.040] (Fig. 3B). No significant impact of sex [F(1,37) = 3.093, p = 0.243] or
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treatment [F(1,37) = 0.855, p = 0.536] was observed. Post hoc analysis showed that vlPAG MOR
expression was significantly reduced in aged males compared with adult males (p = 0.013) (Fig.
3B). To ensure that our observation of reduced vlPAG MOR in aged males was not due to an
age-induced decrease in overall cell number, adjacent sections through the PAG were
immunohistochemically stained using the neuron-specific marker NeuN (Millipore; [75]) and the
density of staining quantified using densitometry. No significant effect of age [F(1,23) = 0.133, p =
0.909] or sex [F(1,23) = 0.072, p = 0.791] was observed in NeuN immunostaining (Fig. 3C),
indicating that the reduction in MOR density was not due to an overall age-related loss in
neuronal number. We further examined if the reduction in MOR observed in aged males was
limited to the PAG or present in other MOR-containing regions. Sections through the IC, a
region rich in MOR, were stained and quantified. No significant effect of age [F(1,12) = 0.094, p =
0.764] or sex [F(1,12) = 0.029, p = 0.868] on MOR expression was noted, suggesting the ageinduced reduction in MOR expression was specific for the PAG (Fig. 3D).
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Figure 2.3 MOR expression
Representative section from rat brain with red highlight showing the vlPAG region quantified for MOR
immunoreactivity (A). MOR densitometry in the vlPAG was significantly lower in aged rats compared with adults
(B). No significant impact of sex or treatment was noted. No differences MOR density was observed between
handled and CFA treated groups, so these data are combined. No significant effect of age or sex was observed in
NeuN densitometry in the vlPAG (C). No significant effect of age or sex was observed in MOR densitometry in the
inferior colliculus (IC) (D). ∗Significant difference between adult and aged males; p < 0.05 calculated by Tukey's
post hoc test. ns, not significant. Graphs indicate mean ± SEM.

2.4.4

Impact of advanced age, sex, and chronic pain on MOR binding in the
midbrain vlPAG

We next used autoradiography to determine if the observed reduction in MOR expression
in aged males reflected a reduction in MOR binding. [3H]-DAMGO was used to label MOR as
previously described (LaPrairie & Murphy, 2009). Representative autoradiograms are shown in
Fig. 4A. Consistent with what we noted using IHC, there was a significant impact of age [F(1,39) =
30.08, p < 0.0001], with aged rats exhibiting a loss of binding compared than their adult
counterparts (Fig. 4B). Post hoc analysis indicated that aged males had reduced MOR binding
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compared with adult males [p = 0.0067]. MOR binding was also significantly reduced in aged
females compared with adults [p = 0.0009]. There was no significant impact of sex [F(1,39) =
0.108, p = 0.306] or treatment [F(1,39) = 0.021, p = 0.885] (Fig. 4B), and no significant
interactions were noted.

Figure 2.4 MOR saturation binding
Heat mapped representative images of DAMGO binding in the midbrain of experimental groups (A). Aged
rats exhibited reduced PAG MOR binding compared with adults (B). No impact of sex was found. No differences in
density were observed between handled and CFA-treated groups, so these data are combined. Data presented in
disintegrations per minute per milligram. ∗ Significant difference between adult males and females and aged rats; p
< 0.05 calculated by Tukey's post hoc test. Graphs indicate mean ± SEM.
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2.5

Discussion
The present studies were conducted to determine the impact of advanced age on opioid

modulation of pain. Using a more clinically relevant model of persistent inflammatory pain, we
report that aged rats require higher doses of morphine than their adult counterparts to achieve
comparable levels of analgesia. The impact of age was sex specific, such that aged males
required a significantly higher morphine dosage to reach analgesia than adult males; no impact of
age was noted in morphine potency in females. Our results further demonstrate significant age
differences in vlPAG MOR expression, with aged rats exhibiting reductions in vlPAG MOR
protein and binding. As MOR expression and function in the vlPAG is critical for morphine
attenuation of pain, the observed age-induced reduction in vlPAG MOR may drive the reduced
morphine potency observed in aged rats.

Figure 2.5 Study summary
Aged rats exhibit reduced morphine anti-huperalgesic potency and reduced vlPAG MOR expression
and binding compared to adult males

42

2.5.1

No impact of advanced age or sex on baseline pain sensitivity and CFA-induced
hyperalgesia

In the present studies, no effect of advanced age (or sex) was observed in baseline
thermal sensitivity. This finding is consistent with our previous studies as well as those of others
(Ali et al., 1995; Craft et al., 1998; Craft & Milholland, 1998; X. Wang et al., 2006). Indeed,
most rodent studies assessing the impact of sex on basal nociception report no differences(Mogil
et al., 2000; X. Wang et al., 2006; Mogil et al., 2010; Racine et al., 2012; Mogil, 2020). In a
recent meta-analysis of studies published as of August 2019, only 8% (41/526) reported a
significant quantitative sex difference in pain sensitivity (Mogil, 2020). In regards to ageassociated changes in basal nociception, these reports are highly varied, with reports of increased
(Hess et al., 1981; Kitagawa et al., 2005), decreased (Chan & Lai, 1982; Kramer & Bodnar,
1986; Garrison & Stucky, 2014; Muralidharan et al., 2020), and no change in mechanical or
thermal pain sensitivity in aged rodents compared with adults (Crisp et al., 1994; Taguchi et al.,
2010; Yezierski, 2012; Mecklenburg et al., 2017; Samir et al., 2017). Similarly, meta-analyses of
both clinical and laboratory measurements in humans fail to report a consistent impact of age on
nociception(Gibson & Helme, 2001; Weyer et al., 2016; Ostrom et al., 2017). For example, in a
meta-analysis summarizing the findings of 52 clinical research studies, Lautenbacher (2012)
concluded that aged individuals exhibit increased pain thresholds (i.e., decreased sensitivity)
compared with young adults (Lautenbacher, 2012). However, these data included both pain-free
individuals and individuals who were experiencing chronic pain and did not include sex as a
variable of analysis. A similar study by Ostrom et al. (2017) of over 3400 participants reported
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no impact of age on pain sensitivity across numerous modalities (pressure, mechanical, and
thermal), although a limited age range was examined (18–44 years) (Ostrom et al., 2017).

In the present study, intraplantar injection of the mycobacterium complete Freund's
adjuvant was used to induce persistent inflammatory pain (Millan et al., 1988; Stein et al., 1988).
We report no significant impact of either age or sex on the magnitude of thermal hyperalgesia
elicited by intraplantar CFA or CFA-induced edema (Loyd & Murphy, 2006; X. Wang et al.,
2006; Loyd et al., 2008). To date, very few preclinical studies have examined the impact of age
on persistent pain. Mecklenburg et al. (2017) reported no impact of age (3, 6, 18, and 24 months)
on either mechanical or thermal hyperalgesia in male mice using a plantar incisional model of
pain (Mecklenburg et al., 2017). Similar results were reported by Garrison and Stucky (2014) in
male mice aged 3 and 24 months after intraplantar CFA. This study also reported comparable
levels of edema in adult and aged mice up to 8 weeks post-CFA (Garrison & Stucky, 2014). In
contrast, Weyer et al. (2016) reported that aged male mice (18 weeks) showed decreased
mechanical hyperalgesia in comparison with adults across all eight weeks examined. This
attenuated hyperalgesic response was accompanied by an overall reduction in noxious stimulusevoked action potentials in the dorsal horn. Similar to the present study, no impact of age on
CFA-induced edema was reported (Weyer et al., 2016).

2.5.2

Impact of advanced age and sex on morphine analgesia

The present studies are the first to examine the impact of advanced age on opioid
modulation of persistent inflammatory pain in male and female rats. We report morphine EC50
values dependent on age and sex; notably, aged male rats required significantly higher doses than
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their adult counterparts to produce comparable antihyperalgesia. Similar results were reported by
Muralidharan et al. (2020), who noted a reduction in morphine's antiallodynic effect in male
mice 54 weeks of age. Interestingly, the antiallodynic effects of the gabapentinoid pregabalin
were also attenuated (Muralidharan et al., 2020), suggesting that the age-induced blunting of
analgesics on pain is not limited to opioids, but rather, extend to other classes of drugs.

Clinically, several studies report that opioid requirements for postoperative pain are
inversely related to age (Kaiko, 1980; Gagliese & Katz, 2003; Keïta et al., 2008), although
results to the contrary have also been reported (Papaleontiou et al., 2010; Prostran et al., 2016).
The results from clinical studies on elderly individuals are more challenging to interpret due to
the high degree of comorbidity with conditions such as heart disease, diabetes, and high blood
pressure that may alter the perception of pain and necessitate the use of concomitant
medications. Additional factors that have been shown to influence clinical studies on pain and
analgesia are sex and age differences in the likelihood of self-reporting pain in a clinical setting
and the subjective nature of pain (B. R. Ferrell et al., 1991; Reddy et al., 2012; Dampier et al.,
2013).

2.5.3

Sex and age differences in vlPAG MOR expression and binding

The PAG is a critical neural site for opioid modulation of pain (Reynolds, 1969;
Behbehani & Fields, 1979; Morgan et al., 1991, 1992; Y. Zhang et al., 1998; Loyd et al., 2008).
In the present study, using both immunohistochemistry and autoradiography, we report that aged
rats exhibit reduced vlPAG MOR expression and binding compared with adults. This suggests
that the age-induced decrease in morphine potency is driven, in part, by diminished vlPAG
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MOR. In the present study, morphine was administered systemically, and the analysis of MOR
expression was limited to the PAG (and IC); therefore, a contribution from other pain-associated
MOR+ regions (including the rostral ventromedial medulla and spinal cord dorsal horn) cannot
be ruled out. Previous studies have reported an attenuation in MOR in the frontal cortex and
striatum of aged male rats compared with adults (Hess et al., 1981; Messing et al., 1981).
Reduced MOR binding in the midbrain and thalamus of aged female rats has also been shown
(Messing et al., 1980). Together, these studies suggest that the reduction in MOR observed in
aged rats is not specific to the PAG. Importantly, we did not find a significant reduction in MOR
in the IC as a function of age or sex, suggesting that these age-associated changes may be limited
to CNS sites implicated in pain and reward. No reduction in neuronal number within the vlPAG
was observed, indicating that the observed reduction in MOR was not due to overall neuronal
loss.

No impact of persistent inflammatory pain on MOR expression or binding in the vlPAG
was noted. Similarly, Thompson et al. (2018) reported no change in MOR availability or
expression in the PAG of male rats after induction of neuropathic pain, although decreased MOR
was observed in the caudate putamen and insula (Thompson et al., 2018). In contrast, Zollner et
al. (2003) reported increased MOR binding in the dorsal root ganglia after intraplantar CFA
(Zollner et al., 2003), suggesting that the effects of persistent inflammatory pain on MOR are
region-specific. Clinical studies utilizing positron emission tomography scans to assess for
changes in MOR binding reported that individuals experiencing rheumatoid arthritis pain exhibit
decreased MOR binding in the straight gyrus and the frontal, temporal, and cingulate cortices
(Jones et al., 1994); in addition, individuals experiencing fibromyalgia pain exhibited reduced
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MOR binding in the nucleus accumbens, amygdala, and cingulate cortex (Harris et al., 2007).
Neither of these studies reported an impact of pain on MOR binding in the PAG. A third study
examining MOR binding in individuals experiencing poststroke neuropathic pain (centrally
versus peripherally localized) reported reduced PAG MOR binding in individuals experiencing
neuropathic pain localized centrally not peripherally, compared with controls (Maarrawi et al.,
2007). Together, these results suggest that PAG MOR expression and binding may be altered as
a function of the pain location or modality.

In the present study, we found no impact of sex on vlPAG MOR expression. These
results are contradictory to our previous findings in which we reported significantly reduced
levels of vlPAG MOR in adult females compared to males (Loyd et al., 2008). In that study, sex
differences in MOR were primarily driven by diestrus females, with smaller, nonsignificant
differences noted for the other stages of estrus in comparison with males. In the present study,
although the estrus stage was determined, it was not included as a factor of analysis due to a lack
of power. However, failure to include estrus as a variable of analysis is unlikely to account for
the finding of no sex difference in MOR expression. Rather, methodological differences between
the 2 studies likely contributed to these conflicting results, including differences in antibody
specificity and 3-dimensional confocal versus 2-dimensional light-field microscopy image
acquisition and assessment of MOR density.

The finding of no significant effect of sex on vlPAG MOR expression or binding
suggests that the observed sex differences in morphine potency are not driven by vlPAG MOR
expression or binding as previously proposed (Loyd et al., 2008). Recent attention has focused
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on sex differences in neuroimmune signaling, and in particular, microglia, as a contributing
factor to morphine's dimorphic effects (Sorge et al., 2011; Rosen et al., 2017; Doyle & Murphy,
2017; Eidson & Murphy, 2019; Eidson et al., 2019). In addition to binding to neuronal MOR,
morphine has been shown to bind to the innate immune receptor toll-like receptor 4 (TLR4),
localized primarily on microglia (Hutchinson et al., 2007, 2008, 2010). Morphine action at TLR4
has been shown to decrease both glutamate transporter (GLT1 and GLAST) and GABAA
receptor expression and upregulate AMPA receptor, resulting in an overall increase in neural
excitability (Song & Zhao, 2001; Ogoshi et al., 2005; Stellwagen et al., 2005; Holdridge et al.,
2007; X. Wang et al., 2012; Eidson et al., 2017). As morphine works primarily via
hyperpolarization (Chieng & Christie, 1996), this increased neural excitability within the vlPAG
directly opposes morphine action (Ingram et al., 1998). Our laboratory has recently reported that
blockade of vlPAG TLR4 signaling via (+)-naloxone results in a 2-fold leftward shift in the
morphine dose response curve in females but not males (Doyle et al., 2017). Further, we report
that pathogenic activation of TLR4 via systemic administration of the bacterium
lipopolysaccharide results in a significantly higher vlPAG expression of the proinflammatory
cytokine IL-1ß. Reduced vlPAG expression of the anti-inflammatory cytokine IL-10 was noted
in females, but not males, after lipopolysaccharide. Increased levels of neuroinflammation have
been reported in aged animals suggesting that changes in neuroimmune signaling, along with the
observed reduction in vlPAG MOR binding, together contribute to the reduction in morphine
efficacy (Gorelick, 2010; VanGuilder et al., 2011; Norden & Godbout, 2013). The impact of
advanced age on morphine potency may also be driven by age differences in receptor affinity
and opioid signaling in the vlPAG. Studies are currently underway to assess the impact of age
and sex on vlPAG MOR binding potential and agonist stimulated G-protein activation.
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3.1

Abstract
Opioids have decreased analgesic potency (but not efficacy) in aged rodents compared to

adults; however, the neural mechanisms underlying this attenuated response are not yet known.
The present study investigated the impact of advanced age and biological sex on opioid signaling
in the ventrolateral periaqueductal gray (vlPAG) in the presence of chronic inflammatory pain.
Assays measuring mu opioid receptor (MOR) radioligand binding, GTPγS binding, receptor
phosphorylation, cAMP inhibition, and regulator of G-protein signaling (RGS) protein
expression were performed on vlPAG tissue from adult (2-3mos) and aged (16-18mos) male and
female rats. Persistent inflammatory pain was induced by intraplantar injection of Complete
Freund’s Adjuvant (CFA). Adult males exhibited the highest MOR binding potential and highest
G-protein activation (activation efficiency ratio) in comparison to aged males and females (adult
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and aged). No impact of advanced age or sex on MOR phosphorylation state was observed.
DAMGO-induced cAMP inhibition was highest in the vlPAG of adult males compared to aged
males and females (adult and aged). vlPAG levels of RGS4 and RGS9-2, critical for terminating
G-protein signaling, were assessed using RNAscope. Adult rats (both males and females)
exhibited lower levels of vlPAG RGS4 and RGS9-2 mRNA expression compared to aged males
and females. The observed age-related reductions in vlPAG MOR binding potential, G-protein
activation efficiency, and cAMP inhibition, along with the observed age-related increases in
RGS4 and RGS9-2 vlPAG expression, provide potential mechanisms whereby the potency of
opioids is decreased in the aged population.

3.2

Significance Statement
Opioids have decreased analgesic potency (but not efficacy) in aged rodents compared to

adults; however, the neural mechanisms underlying this attenuated response are not yet known.
In the present study, we observed age-related reductions in vlPAG MOR binding potential, Gprotein activation efficiency, and cAMP inhibition, along with the observed age-related increases
in RGS4 and RGS9-2 vlPAG expression, providing potential mechanisms whereby the potency
of opioids is decreased in the aged population. These coordinated decreases in opioid receptor
signaling may explain the previously reported reduced potency of opioids to produce pain relief
in females and aged rats.
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3.3

Introduction
Clinical studies examining pain management in the elderly are challenging; co-morbid

conditions such as diabetes and high blood pressure and participant use of concomitant
medications affect patient outcomes, contributing to difficulties in the interpretation of results
(Naples et al., 2016; Prostran et al., 2016). Additionally, there exist age- and sex-related
individual differences in the likelihood of reporting pain in a clinical setting which may lead to
misrepresentations of analgesic efficacy (Reddy et al., 2012; Dampier et al., 2013). Particularly,
aged populations are known to underreport pain due to fears of institutionalization and concerns
with addiction and overdose (B. A. Ferrell et al., 1990; Hofland, 1992).
Using a preclinical model of persistent inflammatory pain (intraplantar Complete
Freund’s Adjuvant; (CFA)), we have previously reported a significant impact of age and sex on
morphine potency. Specifically, we showed that aged rats (18mos) exhibit decreased morphine
potency compared to adults (2mos), with aged males requiring greater than 2x the concentration
of morphine than their adult counterparts to produce equivalent analgesia (Fullerton et al., 2021).
Similar results have been reported in prior preclinical studies, suggesting that aged rodents
require higher doses of opioids to produce antinociception (Webster et al., 1976; Kavaliers et al.,
1983; Kramer & Bodnar, 1986). The mechanisms underlying the attenuation of opioid potency in
the aged population are currently unknown.
Morphine-induced analgesia is mediated primarily via binding to μ-opioid receptors
(MOR), seven-transmembrane domain G-protein coupled receptors (GPCRs) located
predominantly on neuronal cell membranes (Martin, 1963; Wolozin & Pasternak, 1981;
Goodman & Pasternak, 1985; Serohijos et al., 2011). Following agonist binding, coupled Gproteins undergo a conformational change in which the guanosine diphosphate (GDP) bound to
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the inactive alpha subunit is replaced by guanosine triphosphate (GTP), activating the subunit
and promoting opioid signaling through interaction with downstream effectors (Senese et al.,
2020). MORs are coupled to a family of G-proteins called Gi/o that signal via inhibition of
adenylyl cyclase and subsequently decrease cyclic adenosine monophosphate (cAMP) (Koehl et
al., 2018; Bouchet et al., 2021). This G-protein signaling is downregulated or terminated by
Regulator of G-Protein Signaling (RGS) proteins, which act as GTPase activating proteins
(GAPS), hydrolyzing the active GTP back into GDP and terminating downstream signaling
(Gerber et al., 2016). RGS proteins, particularly RGS4 and RGS9-2, have been previously
implicated in opioid-mediated G-protein signaling, and have been shown to attenuate analgesia
(Garnier et al., 2003; Psifogeorgou et al., 2007; Avrampou et al., 2019; Senese et al., 2020). A
primary target of MOR downstream signaling is the effector adenylyl cyclase (AC). AC
enzymatically converts adenosine triphosphate (ATP) to the excitatory second messenger cAMP.
MOR binding inhibits AC, thereby reducing cAMP expression, facilitating neuronal
hyperpolarization, and promoting analgesia (Santhappan et al., 2015). Like other G-protein
coupled receptors, MOR signaling is subject to desensitization via the cellular mechanism of
receptor phosphorylation, which limits agonist binding and recruits arrestin proteins and thus
attenuates opioid signaling. (L. Zhang et al., 1996; Yu et al., 1997; Groer et al., 2011).
The present studies test the hypothesis that the observed age-induced reduction in
morphine potency is mediated by changes in MOR signaling within the midbrain periaqueductal
gray, a CNS region critical for the opioid modulation of pain. (Basbaum et al., 1976; Behbehani
& Fields, 1979; Morgan et al., 1992, 2006). The ventrolateral PAG (vlPAG) contains a large
population of MOR+ neurons, and direct administration of MOR agonists into the PAG produces
potent analgesia (Satoh et al., 1983; Jensen & Yaksh, 1986; Bodnar et al., 1988; Loyd et al.,
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2008) Intra-PAG administration of MOR antagonists or lesions of PAG MOR significantly
attenuate the analgesic effect of systemic morphine, suggesting a critical role for PAG MOR in
mediating morphine action (Ma & Han, 1991; Y. Zhang et al., 1998; Loyd et al., 2008).
We have previously shown that aged rats exhibit reduced vlPAG MOR protein
expression and reduced MOR agonist binding in the vlPAG compared to adult rats (Fullerton et
al., 2021), suggesting that diminished levels of functioning MOR in the vlPAG contribute to the
attenuated opioid potency seen in the aged. The present studies build on these previous findings
to assess age and sex differences in MOR availability, ligand affinity, phosphorylation, G-protein
activation, cAMP inhibition, and expression of RGS proteins.

3.4

Materials and Methods
3.4.1

Experimental subjects

Adult (2-3mos) and aged (16-18mos) male and regularly cycling female Sprague–Dawley
rats were used in these experiments (Charles River Laboratories, Boston, MA). Rats were cohoused in same-sex pairs on a 12:12 hour light/dark cycle (lights on at 08:00 am). Access to food
and water was ad libitum throughout the experiment, except during testing. All studies were
approved by the Institutional Animal Care and Use Committee at Georgia State University and
performed in compliance with Ethical Issues of the International Association for the Study of
Pain and National Institutes of Health. All efforts were made to reduce the number of rats used in
these experiments and to minimize pain and suffering. All assays were performed on separate
cohorts of rats (n=8/sex/age; N=32), with the exception of the radioligand binding and GTPγS
assays, which were run simultaneously on PAG tissue from a single cohort.
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3.4.2

Vaginal cytology

Beginning ten days prior to testing, vaginal lavages were performed daily on adult and
aged female rats to confirm that all rats were cycling regularly and to keep daily records of the
stage of estrous. Proestrus was identified as a predominance of nucleated epithelial cells, and
estrus was identified as a predominance of cornified epithelial cells. Diestrus 1 was differentiated
from diestrus 2 by the presence of leukocytes. Rats that appeared between phases were noted as
being in the more advanced stage (Loyd et al., 2007).
3.4.3

CFA-induced chronic pain treatment

72 hours prior to experimentation, persistent inflammatory pain was induced by injection
of complete Freund's adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200μl), suspended in
an oil/saline (1:1) emulsion, into the plantar surface of the right hind paw. Edema was present
within 24 hours of injection, indicated by a >100% change in paw diameter, determined using
calibrated calipers applied midpoint across the plantar surface compared to handled paw.
3.4.4

Membrane preparation for radioligand binding and GTPγS assays

vlPAG membrane protein lysates were prepared from adult and aged, male and female,
handled and CFA treated rats to be used for radioligand binding and GTPγS assays. 72 hours
post-CFA injection or handling, rats were restrained using DecapiCones and decapitated. Brains
were removed rapidly, flash-frozen in 2-methyl butane on dry ice, and stored at −80°C.
Ventrolateral PAG tissue from caudal PAG (Bregma -7.5 through -8.5) was dissected from each
brain using a straight edge razor at -20°C. On the day of the assay, PAG sections were placed in
ice-cold assay buffer (50 mM Tris-HCl, pH 7.4). Tissue was homogenized with a glass dounce
and centrifuged at 20,000g at 4°C for 30 min. The supernatant was discarded and the pellet
resuspended in assay buffer (Zollner et al., 2003; M. Shaqura, Li, Al-Madol, et al., 2016; M.

55
Shaqura, Li, Al-Khrasani, et al., 2016; X. Li et al., 2018). Membrane protein concentration was
calculated using the Bradford Assay, and lysates of vlPAG membrane protein from adult and
aged, male and female, naïve and CFA treated rats (n=4; N=32) were used immediately for
radioligand binding and GTPγS assays.
3.4.5

Saturation radioligand binding assay

Saturation binding experiments were performed on vlPAG membranes using
[3H]DAMGO (specific activity 50 Ci/mmol, American Radiolabeled Chemicals, Missouri).
Briefly, 100 µg of membrane protein was incubated with various concentrations of
[3H]DAMGO (0.5 to 5nM), in a total volume of 1ml of binding buffer (50mM Tris-HCl pH 7.4).
Nonspecific binding was defined as radioactivity remaining bound in the presence of 10 µM
unlabeled naloxone. At the end of the incubation period (1h at RT) bound and free ligands were
separated by rapid filtration over Whatman brand Grade GF/C glass filters (Sigma-Aldrich)
using a sampling vacuum manifold (MilliporeSigma). Filters were washed four times with 5ml
of cold dH20. Bound radioactivity was determined by liquid scintillation spectrophotometry after
overnight extraction of the filters in 3ml of scintillation fluid. All experiments were performed in
triplicate. Bmax and Kd values were determined by nonlinear regression analysis of concentrationeffect curve in GraphPad Prism 9.1.
3.4.6

Agonist-stimulated [35S]GTPγS binding

DAMGO-stimulated [35S]GTPγS binding to PAG membrane protein was assessed by
incubating membrane protein (100ug) in the presence or absence of [35S]GTPγS (0.1nM)
(specific activity 1250 Ci/mmol, American Radiolabeled Chemicals, Missouri) and various
concentrations of DAMGO (2 to 30,000 nM) in assay buffer (20mM Tris, 10mM MgCl2,
100mM NaCl, 0.2mM EGTA, pH 7.4) for 30min at 30°C. Stimulated [35S]GTPγS binding was
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compared to unstimulated binding at each measurement point and presented as percent basal
binding. At the end of the incubation period, bound and free ligands were separated by rapid
filtration over Whatman brand Grade GF/B glass filters (Sigma-Aldrich) using a sampling
vacuum manifold (MilliporeSigma). Filters were washed four times with 5ml of cold buffer (50
mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid scintillation
spectrophotometry after overnight extraction of the filters in 3ml of scintillation fluid. All
experiments were performed in duplicate. Efficacy (Emax) is defined as the maximum percent
stimulation by an agonist; potency (EC50) is defined as the concentration of DAMGO required
for half the maximal response. Emax and EC50 values were determined by nonlinear regression
analysis of concentration-effect curves using Graph Pad Prism 9.1.
3.4.7

Phosphorylated MOR analysis

To assess the impact of advanced age and sex on MOR phosphorylation state, levels of
MOR phosphorylation were analyzed by Western blot. The lysis buffers used and general
methods are the same as reported in (Lei et al., 2017). Briefly, rat PAG samples were
homogenized in ~500 μL of lysis buffer using a glass dounce and rotated overnight at 4°C. The
samples were then spun down at 13,000g for 10 min at 4°C. The resulting lysates were
quantified by DC Protein Assay Kit (Bio-Rad, #500-0111) according to the manufacturer’s
instructions. 50-75 μg of soluble protein per sample (same for all samples in a set) was run on
10% Bis-Tris Bolt PAGE gels (Fisher Scientific, #NW00100BOX) and wet-transferred to
nitrocellulose membrane (Protran 0.2 μm NC, #45-004-001 from Fisher Scientific) at 30V at 4°C
for 2-3 hours. Membranes were blocked using 5% nonfat dry milk in TBS, then blotted for
primary antibody target in 5% BSA in TBST overnight rocking at 4°C. Primary antibodies used
were: pMOR (1:1000, Bioss #bs-3724R), tMOR (1 μg/mL, R&D #MAB6866), and GAPDH
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(1:1000, Invitrogen #MA5-15738). All 3 targets were always probed for on the same blot, using
low pH stripping buffer between each set. Secondary antibodies were used at 1:5000 each in 5%
nonfat dry milk in TBST, rocking for ~1 hr at room temperature. Secondary antibodies used
were: Goat-α-Mouse-IRDye800CW (Fisher Scientific #NC9401841) and Goat-α-MouseIRDye680LT (Fisher Scientific #NC0046410). Target signal was acquired using an Azure
Sapphire imager using the near-infrared channels (658 and 784 nm). Band density was
quantified, and background subtracted using the onboard AzureSpot analysis software. Samples
were run with at least two representatives of each experimental group on the same gel. Adult and
aged, male and female, naïve and CFA treated rats (n=4; N=32) were used for these experiments.
pMOR signal was normalized to the same sample tMOR or GAPDH as indicated, and all
samples were normalized to the Adult Male average on each gel before combining data from
different gels.
3.4.8

DAMGO-induced cAMP inhibition

DAMGO-induced cAMP inhibition was analyzed using a cAMP assay. vlPAG
membrane protein lysates were prepared from adult and aged, male and female, handled and
CFA treated rats. 72 hours post-CFA injection or handling, rats were restrained using
DecapiCones and decapitated. Brains were removed rapidly, flash-frozen in 2-methyl butane on
dry ice, and stored at −80°C. Ventrolateral PAG tissue from caudal PAG (Bregma -7.5 through 8.5) was dissected from each brain using a straight edge razor at -20°C. Briefly, vlPAG tissues
were homogenized in ice-cold lysis buffer containing 0.25-M sucrose, 50-mM Tris–HCl pH 7.5,
5-mM EGTA, 5-mM EDTA, 1-mM phenylmethylsulfonyl fluoride, 0.1-mM dithiothreitol, and
10 μg/ml leupeptin. The homogenized tissues were then centrifuged at 1000×g for 5 min (4 °C,)
and the supernatant was centrifuged at 35000 ×g for 10 min (Viganò et al., 2003). vlPAG
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membrane protein samples (100ug) from adult and aged, male and female, naïve and CFA
treated rats (n=4; N=32) were incubated in 1uM forskolin (FSK) and in the presence or absence
of 10uM DAMGO to stimulate adenylyl cyclase activity. cAMP levels in vlPAG tissue were
determined using the LANCE Ultra cAMP Detection Kit (Perkin Elmer), a time-resolved
fluorescence resonance energy transfer (TR-FRET) cAMP immunoassay. Data are plotted as %
change in TR-FRET signal comparing FSK baseline measurements to measurements following
DAMGO-stimulated cAMP inhibition.
3.4.9

Single-molecule fluorescence in situ hybridization

Single-molecule fluorescent in situ hybridization (RNAscope) assays were used to
determine mRNA expression of OPRM1, RGS9-2, and RGS4 in the vlPAG. Rats were restrained
using DecapiCones and decapitated. Brains were removed rapidly, flash frozen in 2-methyl
butane on dry ice, and stored RNase free at −80 °C. Frozen tissue was sectioned in a 1:6 series of
20 μm coronal sections at –20 °C with a Leica CM3050S cryostat. Sections were immediately
mounted onto Superfrost slides (20 °C) and stored at −80 °C until the time of the assay. vlPAG
sections from adult and aged, male and female, naïve and morphine treated rats were used (n=47; N=45). For morphine dosing paradigm, see (Fullerton et al., 2021). Tissue was processed for
single-molecule fluorescence in situ hybridization (smFISH) according to the RNAscope
Multiplex Kit protocol (Advanced Cell Diagnostics) using probes for OPRM1, RGS4, and
RGS9-2. To facilitate cellular mRNA quantification within the vlPAG, sections were
counterstained with DAPI. mRNA puncta were visualized as fluorescent signals. Fluorescent
images were captured on Zeiss LSM 700 Confocal Microscope at 40x, and mRNA expression
(target puncta/DAPI) was calculated using Imaris software. To determine RGS4 and RGS9-2
expression levels in MOR+ neurons, quantification was restricted to puncta located within 10μm
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of DAPI that co-expressed OPRM1 mRNA. mRNA expression values were determined for the
left and right ventrolateral subdivisions of each PAG image from two representative levels of the
mid-caudal PAG (Bregma −7.74 and −8.00). As there was no significant effect of rostrocaudal
level in the analyses, data were collapsed and presented as vlPAG and were averaged for each
rat. RGS4 and RGS9-2 mRNA values are expressed as the mean ± standard error of the mean
(SEM). All images were collected and analyzed by an experimenter blinded to the experimental
condition
3.4.10 Statistical analysis and data presentation
All values are reported as mean ± SEM. Data were assessed for normality and
homogeneity of variance using Shapiro-Wilk and Bartlett’s tests. Significant main effects of sex,
age, and treatment were assessed using ANOVA; p < 0.05 was considered statistically
significant. Tukey’s post-hoc tests were conducted to determine significant mean differences
between groups that were a priori specified. Data are expressed either as fmol/protein or nM
DAMGO for radioligand binding assay or Emax or EC50 for GTPγS assay

3.5

Results
3.5.1

Advanced age and sex impact vlPAG MOR binding properties

To assess the impact of advanced age, biological sex, and pain on vlPAG MOR signaling,
we first used radioligand saturation binding assays to determine MOR binding parameters. The
saturation binding curves generated with [3H]DAMGO are shown in Fig. 1A. CFA treatment did
not significantly impact Kd [F(1,22) = 3.429, p=0.078] or Bmax [F(1,24) = 0.0023, p = 0.963] so CFA
and handled groups were combined.
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Kd values, indicative of receptor affinity, were determined using the concentration-effect
curves generated from each sample. Analysis of Kd values indicated no significant impact of age
[F(1,26) = 0.770, p=0.388] or sex [F(1,26) = 1.241, p=0.275], or a significant interaction [F(1,26) =
1.278, p=0.269] (Fig. 1B).
Analyses of Bmax values, indicative of receptor availability, showed no significant impact
of age [F(1,28) = 2.661, p=0.114] or sex [F(1,28) = 0.002, p=0.967], but a significant interaction
[F(1,28) = 4.995, p=0.034]. Post hoc analysis showed a significant difference in vlPAG MOR
availability between adult males and aged males, as evidenced by reduced Bmax values in the
aged males compared to their adult counterparts (p = 0.025)(Fig. 1C). Bmax values for aged males
were markedly reduced compared to adult males, while adult females and aged females exhibited
smaller reductions in Bmax compared to their adult male counterparts (%Δ -23.6 and -17.1,
respectively. Fig. 1C).
Analyses of binding potential (BP) values, a measure that takes into consideration the
density of available receptors and the affinity of the receptor for its agonist, showed a significant
impact of sex, with males exhibiting greater binding potential than females [F(1,28) = 4.631,
p=0.040] and a significant interaction between age and sex [F(1,28) = 9.110, p=0.005]. No
significant impact of age [F(1,28) = 3.312, p=0.079] was observed. Post hoc analyses showed a
significant difference in vlPAG MOR binding potential between adult males and adult females (p
= 0.006) and adult males and aged males (p = 0.010), indicating that adult males exhibit greater
vlPAG MOR binding potential than their aged male counterparts and their adult female
counterparts (Fig. 1D). Adult females, aged males, and aged females all exhibited marked

61
reductions in MOR binding potential compared to their adult male counterparts (%Δ -52, -48.7,
and -40, respectively; Fig. 1D).

Figure 3.1 MOR binding properties
Saturation binding curve of bound [3H]DAMGO (A). No significant effect of age or sex was observed
in MOR affinity (Kd) (B). MOR availability (Bmax) was significantly lower in aged males compared to adult
males (C). Adult females, aged males, and aged females exhibited reduced MOR binding potential (B max/Kd)
compared to adult males, indicating attenuated agonist interaction at the receptor level (D). CFA treated rats are
represented as circles, handled rats are represented as triangles. ns, not significant. *Significant difference
between adult and aged males, or adult males and adult females; p<0.05 calculated by Tukey’s post hoc test.
Graphs indicate mean ± SEM. Values indicate % change from adult male.
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3.5.2

Advanced age and sex impact opioid-induced G-protein activation in the vlPAG

We next conducted GTPγS binding assays to determine if advanced age or biological sex
impacted MOR mediated G-protein activation. Our initial studies revealed a significant main
effect of chronic pain [F(1, 24) = 29.04, p < 0.0001] (Fig. 2E). To improve the translatability of
these results to the target population of aged patients suffering from chronic pain, all other data
displayed from GTPγS experiments are exclusively from CFA-treated rats. Concentration curves
generated from [35S]GTPγS assays are shown in Fig. 2A. Analyses of Emax values, a measure
of G-protein availability combined with ligand efficacy, indicated no significant impact of age
[F(1,24) = 0.035, p = 0.8532] or sex [F(1,25) = 2.852, p = 0.1042], or a significant interaction
[F(1,24) = 2.023, p = 0.1678] (Fig. 2B).
Analyses of EC50 values, a measure of the concentration of DAMGO required for halfmaximal G-protein binding, indicated a significant impact of sex, with males exhibiting lower
effective concentration values than females, reflecting a higher potency of activation [F(1,24) =
5.177, p = 0.0321]. There was no significant impact of age [F(1,24) = 2.339, p = 0.1393], and no
significant interaction [F(1,24) = 2.473, p = 0.1289] (Fig. 2C). Although not statistically
significant, aged males, adult females, and aged females all exhibited marked increases in Gprotein EC50 compared to their adult male counterparts, as evidenced by their percent change
values (%Δ 60.5, 114.8, and 98.6, respectively), reflecting a lower potency of activation (Fig.
2C). Together, these results suggest that opioid-induced G-protein signaling is impaired in the
PAG of the aged rat and the female rat.
Next, we calculated the coefficient ratio of analysis of Emax / EC50, which is indicative of
overall G-protein activation efficiency. A significant impact of age was noted, with adults
exhibiting higher vlPAG G-protein activation efficiency than aged rats [F(1,24) = 6.491, p =
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0.0177]. There was also a significant impact of sex, with males exhibiting higher vlPAG Gprotein activation efficiency compared to females [F(1,24) =10.39, p = 0.0036]. A significant
interaction was also observed [F(1,24) = 13.93, p = 0.0010]. Post hoc analyses showed a
significant difference in vlPAG G-protein activation efficiency between adult males and aged
males (p = 0.0009), with adult males exhibiting greater vlPAG G-protein activation efficiency
than aged males. A significant difference in vlPAG G-protein activation efficiency between adult
males and adult females (p= 0.0003) was also observed, with adult males exhibiting greater
vlPAG G-protein activation efficiency than adult females (Fig. 2D). Aged males, adult females
and aged females all exhibited marked reductions in G-protein activation efficiency compared to
their adult male counterparts (%Δ -40.0, -52.1, and -41.9, respectively; Fig. 2D).
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Figure 3.2 Figure 3.2 G-protein activation
[35S]GTPγS binding curve of agonist-stimulated GTPγS binding (A). No significant effect of age
or sex was observed in Emax (B). Aged males, adult females, and aged females exhibited increased EC 50
values compared to adult males, indicating that adult males have the greatest potency (C). Aged males,
adult females, and aged females exhibited reduced G-protein activation efficiency (Emax/EC50) compared
to adult males, indicating attenuated G-protein signaling (D). Initial studies using both handled and CFA
treated rats indicated a significant main effect of chronic pain on EC 50 values (E). CFA treated rats are
represented as circles, handled rats are represented as triangles. ns, not significant. *Significant
difference between adult and aged males, or adult males and adult females; p<0.05 calculated by Tukey’s
post hoc test. Graphs indicate mean ± SEM. Values indicate % change from adult male.
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3.5.3

Advanced age and sex do not impact phosphorylated MOR in the vlPAG

The results above showed significant reductions in MOR binding potential and G-protein
activation efficacy. Therefore, we next examined if there was an effect of age and sex on MOR
phosphorylation, as increased levels of pMOR would likely contribute to these reductions.
Western blots were used to determine the impact of advanced age on MOR phosphorylation at
serine-375, a known site of phosphorylation-mediated desensitization (Schulz et al., 2004). There
was no significant impact of treatment on our initial analyses [F(1,16) = 0.0033, p = 0.9547], so
CFA and handled groups were combined. Although increased pMOR/tMOR was observed in
aged males compared to their adult counterparts (%Δ 34.0), no significant main effect of age
[F(1,41) = 2.168, p = 0.1486], sex [F(1,41) = 1.807, p = 0.1863], or age x sex interaction [F(1,41) =
0.4615, p = 0.5008] was observed (Fig. 3).
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Figure 3.3 Phosphorylated MOR
No significant impact of advanced age or biological sex on the ratio of phosphorylated MOR/ total MOR (A
(A). Representative phosphoMOR blots are shown below the graph (B). CFA treated rats are represented as circles, handled rats
are represented as triangles. ns, not significant. Graph indicates mean ± SEM. Values indicate % change from adult male.

3.5.4

Advanced age and sex impact opioid-induced cAMP inhibition in the vlPAG

We next determined if advanced age, biological sex, or persistent pain impacted opioidinduced cAMP inhibition in the vlPAG. Forskolin-induced cAMP release was used as a baseline
measurement for each group, while forskolin + DAMGO was used to assess the degree to which
cAMP was inhibited by DAMGO. Percent change from baseline was used to compare across
treatment groups (Fig. 4A). There was no significant impact of persistent pain on percent change
from baseline [F(1,26) = 0.7619, p = 0.3907], so CFA and handled groups were combined. Our
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analyses revealed a significant main effect of age [F(1,30) = 9.314, p = 0.0047], a significant
main effect of sex [F(1,30) = 10.31, p = 0.0031], and a significant interaction [F(1,30) = 14.24, p
= 0.0007]. Post hoc analyses showed a significant difference in cAMP inhibition between adult
males and adult females (p = 0.0002), adult males and aged males (p = 0.002), and adult males

Figure 3.4 Opioid-induced cAMP inhibition
TR-FRET immunoassay showing % change from FSK stimulated baseline (1uM FSK) to DAMGO-induced cAMP inhibition
DAMGO). cAMP levels are inversely proportional to TR-FRET signal. Adult males exhibited the highest level of agonist-dependent %
cAMP (A). Individual values in 4B indicate each rat’s % change from FSK baseline to DAMGO-induced cAMP inhibition. 2x2 ANOV
to compare across treatment groups. Aged males and females exhibited reduced agonist-dependent cAMP inhibition compared to adult
indicating attenuated downstream opioid signaling (B). CFA treated rats are represented as circles, handled rats are represented as trian
*Significant difference between adult and aged males, or adult males and adult females; p<0.05 calculated by Tukey’s post hoc test. Gr
indicate mean ± SEM. Values indicate % change from FSK baseline.
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and aged females (p = 0.004), indicating that DAMGO elicits greater cAMP inhibition in adult
males compared to aged males and females (both adult and aged) (Fig. 4B).

3.5.5

Advanced age and sex impact RGS4 and RGS9-2 expression in the vlPAG

Regulator of G-protein Signaling (RGS) proteins act as GAP accelerators to negatively
modulate G-protein signaling. RGS protein family members RGS4 and RGS9-2 are expressed in
the vlPAG and have both been shown to regulate opioid signaling by reversing G-protein
activation. Therefore, we next used smFISH to determine if RGS4 and RGS9-2 expression in the
vlPAG was altered by advanced age and biological sex. In these studies, following CFA
administration, a cohort of rats was administered morphine to examine the relationship between
morphine EC50 and RGS levels. No significant impact of morphine treatment on RGS4 [F(1,22)
= 0.8521, p = 0.3664], RGS9-2 [F(1,22) = 0.0258, p = 0.8739], or OPRM1 [F(1,22) = 0.3146, p
= 0.5805] was observed in our initial analyses, so naïve and morphine treated groups were
combined. We first assessed total vlPAG expression of RGS4 and RGS9-2. These analyses
revealed a significant main effect of age on both RGS4 [F(1,37) = 18.15, p = 0.0001] and RGS92 [F(1,37) = 17.09, p = 0.0002], with aged rats exhibiting increased levels of RGS4 and RGS9-2
mRNA compared to their adult counterparts (Fig. 5A & B). No significant main effect of sex on
RGS4 [F(1,37) = 0.0247, p = 0.8763] or RGS9-2 [F(1,37) = 0.4855, p = 0.4903], or significant
interactions between age and sex for RGS4 [F(1,37) = 0.4994, p = 0.4842] or RGS9-2 [F(1,41) =
0.3246, p = 0.5723] were observed (Fig. 5A & B).
Following our assessment of total RGS4 and RGS9-2, we next restricted our analyses to
RGS4 and RGS9-2 mRNA expressed on MOR+ neurons. We first assessed overall OPRM1
mRNA expression in the vlPAG and found no significant main effect of age [F(1,36) = 2.793, p
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= 0.1034], or sex [F(1,36) = 0.076, p = 0.7844], or significant interactions between age and sex
[F(1,36) = 0.7626, p = 0.7892]. Similarly, no significant main effect of age [F(1,41) = 3.556, p =
0.0664], or sex [F(1,41) = 1.170, p = 0.2858], or significant interactions between age and sex
[F(1,41) = 0.071, p = 0.7908] was observed for OPRM1 mRNA expressed specifically on MOR+
neurons. We next determined if RGS4 and RGS9-2 expression was increased preferentially in
OPRM1+ neurons. Similar to what was noted above, a significant main effect of age on
expression of RGS4 [F(1,41) = 26.47, p < 0.0001] and RGS9-2 [F(1,41) = 21.69, p < 0.0001]
was observed, with aged rats exhibiting increased levels of RGS4 and RGS9-2 mRNA in MOR+
neurons compared to their adult counterparts (Fig. 5C & D). No main effect of sex for RGS4
[F(1,41) = 0.7881, p = 0.3799] or RGS9-2 [F(1,41) = 0.0006, p = 0.9799], or significant
interactions between age and sex for RGS4 [F(1,41) = 0.6583, p = 0.4219] or RGS9-2 [F(1,41) =
0.0075, p = 0.9314] were observed (Fig. 5C & D).
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Figure 3.5 RGS4 and RGS9-2 expression
mRNA expression of RGS4 (A) and RGS9-2 (B) in the vlPAG was significantly greater in aged rats
compared to adults. mRNA expression of RGS4 (C) and RGS9-2 (D) on MOR+ cells in the vlPAG was significantly
greater in aged rats compared to adults. No significant impact of advanced age or biological sex on mRNA
expression of OPRM1 (E) or mRNA expression of OPRM1 on MOR+ cells in the vlPAG (F) Photomicrograph of
RGS expression compared an adult male and an aged male PAG section (G). CFA treated rats are represented as
circles, CFA + morphine treated rats are represented as diamonds. *Significant difference between adults and aged
rats; p<0.05 calculated by 2x2 ANOVA. Graphs indicate mean ± SEM.

3.6

Discussion
The present studies are the first to show that advanced age results in a significant

attenuation in MOR signaling within the vlPAG of male and female rats. Specifically, aged
males and females (regardless of age) showed decreased MOR binding potential, decreased Gprotein activation, and decreased agonist-stimulated cAMP inhibition in comparison to adult
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males (Fig. 6). These changes, along with the observed increase in RGS4 and RGS9-2
expression, provide a mechanism whereby morphine potency is significantly reduced in aged rats
(Fullerton et al., 2021).

Figure 3.6 Summary of MOR signaling impairments in the vlPAG of the aged and female rat.
Aged and female rats exhibit decreased MOR binding potential, decreased G-protein activation, and
decreased cAMP inhibition, while aged rats alone demonstrate increased RGS4 and RGS9-2 expression. No
impact of age or sex was found in phosphorylation of MOR at serine-375

3.6.1

Impact of advanced age and sex on MOR binding potential

We previously reported that morphine potency is reduced in aged and female rats, likely
due to a reduction in DAMGO binding in the vlPAG (Fullerton et al., 2021). Here we report
significant reductions in vlPAG MOR binding potential in aged males and females of either age
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in comparison to adult male rats, suggesting the observed decrease in opioid potency is driven, in
part, by reduced expression/availability of MOR in the vlPAG. Notably, no impact of advanced
age or sex on the MOR’s affinity for its ligand (Kd values) was noted. However, aged males had
reduced MOR availability as evidenced by lower Bmax values compared to their adult male
counterparts, a finding consistent with reports of reduced DAMGO binding in the vlPAG of aged
males (Fullerton et al., 2021), and together suggest an age-induced downregulation of PAG
MOR in males matching a consistently lower level of MOR expression in females of any age.
No impact of persistent inflammatory pain on vlPAG MOR binding potential was noted,
consistent with previous studies. For example, patients with chronic fibromyalgia pain exhibit no
changes in MOR binding in the PAG, despite significant reductions in the nucleus accumbens
and amygdala (Harris et al., 2007). Similarly, no change in PAG MOR binding was noted
following chronic pain induced by proximal nerve injury (Maarrawi et al., 2007). In rodents,
persistent inflammatory pain increased MOR binding in the DRG at 24 and 96 hours post-CFA
(Mousa et al., 2001; Zollner et al., 2003), with no change noted for the hypothalamus or spinal
cord (M. A. Shaqura et al., 2004). Similarly, no change in PAG MOR availability or expression
was observed following sciatic nerve injury, although reductions were noted for the insula,
caudate putamen, and motor cortex (Thompson et al., 2018). These results, together, suggest that
chronic pain alters MOR signaling in a CNS region-specific manner.
3.6.2

Impact of advanced age and sex on G-protein activation

Agonist binding at MOR activates Gαi/o -proteins and downstream signaling cascades,
critical for opioid-mediated hyperpolarization (Laugwitz et al., 1993; Connor & Christie, 1999;
Koehl et al., 2018; Mondal et al., 2020). Presently, adult males exhibited greater G-protein
activation efficiency compared to aged males, suggesting that the decreases in opioid potency
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observed in aged males are driven, in part, by attenuated G-protein-MOR coupling. A significant
impact of biological sex on G-protein potency (EC50) was also observed. The mechanism(s) by
which age and sex attenuate potency is not known; these studies used membrane preparations
that would be devoid of soluble signaling regulators. Similarly, the GTPγS molecule itself is not
hydrolyzable and is thus not subject to regulation by GAPs (e.g., RGS proteins). This suggests
that the observed decrease in G-protein activation potency may be due to decreased opioid
receptor expression/availability observed in our binding studies.
Interestingly, the GTPyS assay was the only analysis where an impact of persistent
inflammatory pain was observed and may contribute to previous findings that the analgesic
effects of intrathecal DAMGO are potentiated following inflammation in male rats (Hurley &
Hammond, 2000). While reductions in Gα subunit expression have been reported within the
rostral ventromedial medulla and dorsal horn following intraplantar CFA in adult male rats
(Wattiez et al., 2017), the mechanism whereby this would impact G-protein activation, and not
the other pharmacodynamics of MOR, is unknown. Also unknown are the mechanisms by which
advanced age and sex alter G-protein-MOR signaling. Advanced age results in a global
downregulation of Gαi/o, most notably in the prefrontal cortex (Young et al., 1991; Alemany et
al., 2007; de Oliveira et al., 2019), that is not associated with overall cell loss. Indeed, the Gαi/o
subunit, in particular, appears susceptible to aging, with estimates of reduced expression as high
as 65% in the frontal cortex, hippocampus, substantia nigra, and striatum (de Oliveira et al.,
2019). Although age-induced changes in Gαi/o expression were not assessed specifically in
PAG, a widespread reduction in Gαi/o would likely impact PAG, thereby limiting MOR-Gprotein coupling and reducing both G-protein activation efficiency and opioid potency.
Alternatively, an uncoupling between MOR and Gαi/o and/or a switch in Gα subunit from Gαi/o
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to Gαs cannot be ruled out (Gintzler & Chakrabarti, 2000, 2004, 2006). Indeed, a shift from
Gαi/o to Gαs would similarly increase adenylyl cyclase activity, resulting in reduced
hyperpolarization and decreased morphine potency (Lamberts et al., 2011).

3.6.3

Impact of advanced age and sex on MOR Phosphorylation

The results of the radioligand binding and GTPγS assays suggested that aged and female
rats exhibit decreased receptor expression and activation potency. As MOR can be desensitized
by phosphorylation in its basal state, thereby limiting agonist activation (L. Zhang et al., 1996;
Yu et al., 1997; Groer et al., 2011), we tested this possibility. Although MOR phosphorylation at
serine-375 was higher in aged males compared to adults, this result was not significant,
suggesting that our observed reductions in activation potency are driven by an alternative
mechanism. Furthermore, this finding suggests that age and sex may not impact receptor
desensitization and internalization, which are generally thought to be MOR phosphorylationdependent.
MOR desensitization is canonically mediated by G protein-coupled receptor kinase
(GRK)-dependent phosphorylation of the receptor (J. Zhang et al., 1998; Schulz et al., 2004;
Dang et al., 2009). Although our results suggest no impact of advanced age or sex on GRKmediated MOR phosphorylation, MOR signaling is also desensitized via phosphorylation
through the extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway (Dang et al., 2009).
ERK1/2 phosphorylation stimulates the activity of Gα-interacting protein (GAIP), an RGS
protein that acts as a GTPase activator to reduce opioid signaling at the level of G-protein
activation (Ogier-Denis et al., 2000). Indeed, pharmacological inhibition of ERK1/2
phosphorylation in a rat model leads to improved morphine analgesia (Popiolek-Barczyk et al.,
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2014; Melkes et al., 2020). Thus, the age- and sex-induced changes in morphine potency may be
driven in part by age-induced hyper-phosphorylation of ERK1/2 and result in the downregulation
of G-protein signaling. This represents an alternative explanation for our phosphorylation results,
by which the receptor could still be functionally desensitized/downregulated without changing
canonical phosphorylation.
3.6.4

Impact of advanced age and sex on cAMP inhibition

Agonist binding at MOR elicits a conformational change in the receptor to allow Gprotein α and βγ subunits to interact with downstream effectors. Notably, the Gα subunit binds to
adenylyl cyclase (AC) and inhibits the conversion of adenosine triphosphate (ATP) to cAMP,
limiting the activation of cAMP-dependent protein kinase (PKA) and ultimately inducing higher
levels of hyperpolarization (Christie, 2008; Seseña et al., 2014; Santhappan et al., 2015). Here,
aged males and adult and aged females exhibited significantly lower levels of DAMGO-induced
cAMP inhibition compared to adult males, suggesting an attenuated activity of the α subunit at
the level of AC or a weakened relationship between AC and cAMP. This effect may result from
decreased MOR expression and G-protein activation potency observed above.
3.6.5

Impact of advanced age and sex on RGS protein levels

The inactivation of G-protein signaling is modulated by the activity of RGS proteins via
enhancement of GTPase activity of the α subunit. By promoting the hydrolysis of the alphabound GTP during the active state, RGS proteins hasten the return of the α subunit to the GDPbound inactive state (Roman & Traynor, 2011). RGS proteins play a critical role in negatively
modulating opioid signaling, as morphine analgesia is increased in male mice lacking RGS9-2
(Garzón et al., 2001; Zachariou et al., 2003) and overexpression of RGS4 attenuates MOR
signaling in reconstituted MORs in vitro (Ippolito et al., 2002). We observed increased
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expression of RGS4 and RGS9-2 in the vlPAG of aged rats compared to adults, suggesting
greater GTPase activity and reduced G-protein signaling. Similar results were observed when the
analysis was limited to MOR+ cells, indicating opioid-induced G-protein signaling is subjected
to greater negative regulation in the vlPAG of the aged rat. These results are consistent with Kim
et al. (2005), who reported higher RGS9-2 protein levels in the PAG of 1-year old male rats
compared to 3-week-old rats (Kim et al., 2005). In humans, advanced age is associated with
increased RGS4 expression in the prefrontal cortex (Rivero et al., 2010), suggesting that our
observed increase in RGS4 not be specific to the vlPAG.
No significant impact of advanced age on OPRM1 mRNA expression in the vlPAG was
noted. This result is interesting given our finding of reduced MOR binding in aged rats and
protein expression in aged rats (Fullerton et al., 2021), and suggests that the observed ageinduced reduction of vlPAG MOR protein is a function of impaired translation. Ori et al., 2015
reported reduced expression of several markers necessary to initiate translation, namely EIF3A,
EIF4G3, EIF4A1, and MDN1 in aged mice (Ori et al., 2015), and a recent study using both mice
and fish found that aged brains exhibit decreased proteasome activity and decreased ribosome
assembly (Sacramento et al., 2020). These results suggest an age-induced dysregulation of
protein synthesis in the brain that is conserved across species.
3.6.6

Summary and Conclusions

The present studies are the first to show that sex and advanced age lead to attenuated
vlPAG opioid signaling compared to adult male rats. Taken together with our previous findings,
these results suggest that age- and sex-induced reductions in vlPAG MOR expression and
binding, combined with attenuated downstream MOR signaling, contribute to the diminished
opioid potency reported in aged and female rats (Fullerton et al., 2021). The results of our

77
analyses demonstrate that aged and female rats exhibit reductions in MOR
expression/availability, G-protein activation, and cAMP inhibition, and increased G-protein
regulation by RGS proteins, each of which provides potential therapeutic targets for improved
pain management in the elderly.
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4

GENERAL DISCUSSION

Chronic pain affects over 50 million persons daily, contributing to depression, increased
disability, and early death (Yong et al., 2022). Older individuals suffer from higher rates of
chronic pain than young adults, with over 40% of individuals over 65 suffering from chronic
pain (Larsson et al., 2017). As the US population ages, these individuals represent a key
demographic in chronic pain management. Further, women are more likely to experience chronic
pain than men, indicating a critical need for individualized therapeutic strategies based on both
age and sex for effective pain management. Opioids are among the most common and most
effective medications for severe pain, with greater than 25% of Americans using opioids each
year (Han et al., 2017). However, proper opioid use for the management of severe pain in the
elderly remains a controversial topic due to a lack of knowledge regarding opioid
pharmacodynamics in the aged.
As discussed in Chapter 1, a clinical assessment of opioid potency for pain relief reported
that both men and women >74 years of age required higher daily doses of morphine to manage
cancer pain compared to men and women <65 years of age (Loick et al., 2000). This suggests
that opioid potency is attenuated in aged humans, however, the mechanisms of this reduced
potency are not known. The present studies address a critical need for effective pain management
in the elderly by defining the influence of advanced age on brain mechanisms subserving pain
and analgesia.
Our findings indicate that aging is associated with decreased mu opioid receptor (MOR)
availability, decreased opioid-induced G-protein signaling, and decreased opioid-induced cAMP
inhibition within the ventrolateral periaqueductal gray (PAG). Taken together, these results
suggest that advanced age causes a decrease in PAG MOR receptor density, resulting in a
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decreased number of activated G-proteins and attenuated inhibition of downstream cAMP.
Further, females exhibit decreased vlPAG MOR binding potential, opioid-induced G-protein
signaling, and cAMP inhibition compared to males. No impact of advanced age or biological sex
was observed on constitutive MOR phosphorylation. Finally, the present studies indicate that
aged males and females exhibit increased vlPAG RGS4 and RGS9-2 expression compared to
their young adult counterparts.
Our observed results suggest several potential mechanisms of action whereby sex and age
impact analgesic potency. First, ligand affinity (Kd) and receptor phosphorylation state were not
significantly different across age and sex suggesting that individual receptor functionality is
comparable within the PAG. In contrast, we did observe a significant decrease in
expression/availability (Bmax) in aged males suggesting decreased available MOR, and not an
attenuation in MOR sensitivity, contributes to the reduced potency of morphine. This ageinduced reduction in PAG MOR signaling might explain the observed decrease in opioidinduced G-protein activation observed in the PAG of our aged rats. As soluble regulators (like
RGS proteins) are absent in this assay and the 35S-GTPγS is non-hydrolyzable, the decrease in Gprotein coupling potency is likely due to decreased receptor availability. Downstream of the Gproteins, we also observed a decrease in cAMP inhibition. This result may be due to the observed
increase in RGS4 and RGS9-2 expression which would decrease G protein activity, leading to
less cAMP inhibition. However, RGS expression was not increased in adult females suggesting a
contribution of additional mechanisms. Overall, our results identify two primary, and
complementary, mechanisms whereby opioid signaling is reduced within the vlPAG: 1)
decreased receptor expression/availability in adult females and aged males and females, and 2)
increased RGS4 and RGS9-2 expression in aged males and females. Further investigation may
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also uncover additional complementary sex- and age-related mechanisms that contribute to the
lower analgesic potency of morphine in females and the aged.
4.1

Advanced age and sex alter morphine anti-hyperalgesia but not thermal nociception

The present studies use intraplantar administration of Complete Freund’s Adjuvant (CFA) to
induce persistent inflammatory pain. This method of peripheral pain induction has been used to
model persistent pain in several mammalian species including humans and has been used
extensively in mouse and rat studies, including multiple studies in our laboratory (Loyd &
Murphy, 2006; X. Wang et al., 2006; Loyd et al., 2007). CFA injection induces moderate
hyperalgesia and edema within hours of injection via local innate immune response (Watkins et
al., 1994; Raghavendra et al., 2004). In rodents, CFA-induced hyperalgesia perpetuates for 7
days, at which point it beings to improve, ultimately resolving by 14 days post-administration
(Millan et al., 1988; Stein et al., 1988; Philippe et al., 1997; Goff et al., 1998; X. Wang et al.,
2006). Intraplantar injection of CFA emulates the time course of clinical pain produced by
surgery and peripheral injury, conditions that are typically managed by opioids (Millan et al.,
1988; Stein et al., 1988). Thus, intraplantar CFA provides a reliable and clinically relevant rodent
model of persistent peripheral pain.
Studies described in Chapter 2 examined the impact of advanced age and/or biological sex on
nociceptive thresholds. These studies included 4 treatment groups: adult males (2 months of
age), adult females (2 months of age), aged males (16-20 months of age), and aged females (1620 months of age). Basal withdrawal thresholds in response to a noxious thermal stimulus were
determined using the Hargreaves assay (Hargreaves et al., 1988). Our results showed no
significant effect of sex on baseline thermal sensitivity, a finding consistent with previous studies
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from our laboratory in addition to those of others (Ali et al., 1995; Craft & Milholland, 1998;
Craft et al., 1999; X. Wang et al., 2006). Indeed, meta-analyses find that the majority of rodent
studies report no sex differences in basal nociception (Mogil et al., 2000, 2010; Racine et al.,
2012; Mogil, 2020) and that only 8% (41/526) of such studies published as of August 2019 find a
significant impact of biological sex on basal pain sensitivity (Mogil, 2020).
Our results further showed no significant effect of advanced age on baseline thermal
sensitivity. Previous studies examining the impact of age on basal thermal pain sensitivity are
contradictory, with reports of increased (Hess et al., 1981; Kitagawa et al., 2005), decreased
(Chan & Lai, 1982; Kramer & Bodnar, 1986; Garrison & Stucky, 2014; Muralidharan et al.,
2020), and no change in mechanical or thermal pain sensitivity in aged rodents compared to
adults (Islam et al., 1993; Crisp et al., 1994; Jourdan et al., 2002; Taguchi et al., 2010; Yezierski,
2012; Mecklenburg et al., 2017; Samir et al., 2017). Multiple factors may contribute to these
disparate results, notably the species used, the range of ages for aged and adult groups, the pain
assay used (e.g., thermal, mechanical, visceral), and the chronicity of the pain (acute, persistent).
Clinical studies similarly fail to report a consistent impact of advanced age on basal pain
sensitivity. A meta-analysis summarizing the findings of 52 clinical research studies reported
that aged individuals exhibit decreased pain sensitivity compared to young adults (Lautenbacher,
2012). However, this analysis included both pain-free individuals and individuals experiencing
chronic pain. This is a major confound as individuals experiencing chronic pain commonly use
prescription medications and are more likely to suffer from additional disabilities.
In addition to basal pain, we also examined the impact of advanced age and sex on persistent
inflammatory pain induced by intraplantar CFA. Pre-clinical studies in rodents from our lab and
others demonstrate that females require approximately two times as much morphine as young
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adult males to achieve comparable analgesia (Craft et al., 1999; Ji et al., 2006; X. Wang et al.,
2006; Loyd et al., 2008). Studies conducted in a laboratory setting with aging rodents suggest
that aged rats are also less sensitive to the analgesic effects of opioids, and thus require higher
doses for adequate analgesia (Kavaliers et al., 1983; Jourdan et al., 2002). A primary flaw in the
design of extant studies is the continued use of acute ‘evoked response’ pain assays rather than
using a persistent pain assay. In addition, as with clinical reports, these aging studies fail to
include sex as a variable of analysis. The inclusion of females and the use of animal models of
pain that reflect the pathophysiological processes of clinically-diagnosed pain in humans are
required to address the knowledge gap left by existing preclinical studies of pain (King &
Porreca, 2014).
Consistent with our previous studies, we found no significant impact of sex on CFAinduced hyperalgesia or CFA-induced edema (Loyd & Murphy, 2006; X. Wang et al., 2006;
Loyd et al., 2008). Further, no impact of advanced age on CFA-induced hyperalgesia or edema
was noted, with adult and aged rats exhibiting equivalent nociceptive thresholds. Relatively few
preclinical studies have assessed the impact of advanced age on hyperalgesia. Consistent with
our results, (Garrison and Stucky, 2014) reported no differences in intraplantar CFA-induced
hyperalgesia or edema in adult (3 mos) versus aged male mice (24 mos)(Garrison & Stucky,
2014). Similarly, no impact of age (3 to 24 months) on thermal or mechanical hyperalgesia was
noted in a mouse model of plantar incisional pain (Mecklenburg et al., 2017). Alternatively,
(Weyer et al., 2016) reported that following intraplantar CFA administration, aged male mice (18
mos) exhibited decreased mechanical hyperalgesia in comparison to adults. This hyperalgesia
was accompanied by a reduction in noxious stimulus-evoked action potentials in dorsal horn
neurons. Similar to the present study, no impact of age on CFA-induced edema was reported
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(Weyer et al., 2016), suggesting that age-dependent changes in mechanical hypersensitivity are
not dependent on CFA-induced edema.
Our studies examined the impact of advanced age on opioid modulation of persistent
inflammatory pain in male and female rats. We report that aged male rats exhibit reduced
morphine anti-hyperalgesic potency compared to young adult males. Indeed, aged males required
significantly higher doses of morphine than their young adult counterparts to produce
comparable modulation of persistent pain. These results are consistent with prior research on
male mice; Muralidharan et al. (2020) reported that mice exhibit reduced morphine antiallodynic potency at 54 weeks compared to 10 weeks. This group also reported attenuated antiallodynia produced by the gabapentinoid pregabalin in aged male mice, suggesting that aged
rodents are less sensitive to not only opioids but to other classes of analgesics as well
(Muralidharan et al., 2020).
Importantly, this age-induced attenuation in morphine potency (Chapter 2) is not due to
age/sex differences in basal thermal somatosensory thresholds or CFA-induced hyperalgesia or
edema. Rather, our findings suggest that age has a specific impact on central opioidergic
signaling.
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4.2

Advanced age and sex modulate vlPAG MOR expression and ligand binding
The PAG, along with its projections to the rostral ventromedial medulla (RVM), is critical

for opioid modulation of pain (Reynolds, 1969; Behbehani & Fields, 1979; Morgan et al., 1991,
1992; Y. Zhang et al., 1998; Loyd et al., 2008). Mu opioid receptor, the preferred receptor for
morphine, is localized within the vlPAG, and several lines of evidence suggest that vlPAG MOR
is critical for opioid modulation of pain. First, intra-PAG injection of the MOR antagonist (-)naloxone attenuates the effects of stimulation-induced analgesia (Akil et al., 1976). Secondly,
lesions of PAG MOR, induced by site-specific injections of the ribotoxin saporin conjugated
with a potent MOR agonist dermorphin, completely attenuate systemic morphine-induced
analgesia in male rats (Loyd et al., 2008). The present studies (Chapter 2) report that aged males
and females exhibit reduced morphine potency, as
indicated by increased morphine EC50 values. Further, our
data (Chapters 2 & 3) indicate that aged males exhibit
reduced PAG MOR expression compared to young adult
males; similarly, aged males and females exhibit reduced
MOR binding compared to adult males and females.
Taken together, these findings suggest that age-induced
changes in PAG MOR expression and binding contribute
to reduced opioid potency in aged rodents.
Using immunohistochemistry (for protein localization)
and autoradiography (for quantification of ligand binding)
we report that aged rats exhibit reduced vlPAG MOR
expression and binding compared to adults (Figure

Figure 4.1 MOR expression and binding
MOR expression was assessed using
immunohistochemistry, MOR binding was
assessed using autoradiography
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4.1). As a negative control, we also assessed the impact of advanced age on MOR expression
within the inferior colliculus (IC), a brain region rich in MOR but not implicated in pain or
opioid analgesia. We found no sex or age differences in IC MOR, suggesting that the ageassociated reduction in MOR was limited to the PAG. However, as we did not conduct a
widespread survey of CNS regions, we cannot definitively rule out if advanced age alters MOR
expression in other brain regions.
The results of our autoradiography experiments showing reduced DAMGO binding in the
vlPAG of aged rats (Chapter 2) were supported by parallel findings using saturated radioligand
binding assays (Chapter 3). We report that aged males exhibit reduced MOR availability as
evidenced by lower Bmax values compared to young adult males. These results, together, provide
corroborating evidence suggesting that the decrease in opioid potency observed in the aged rats
is driven, in part, by reduced expression/availability of MOR in the vlPAG.
Interestingly, results from our radioligand binding assay show a significant reduction in
Bmax values for aged males compared to adult males; in contrast, aged females did not differ
significantly from adult males. These results are inconsistent with those generated using
autoradiography, which showed significantly reduced DAMGO binding in both aged males and
aged females compared to young adults (Chapter 2). These conflicting results may be due to
methodological differences between receptor autoradiography and radioligand binding. Receptor
autoradiography was performed using a single concentration of DAMGO applied to 20-micron
tissue sections, while the radioligand binding assays were performed on membrane protein
lysates derived from dissected vlPAG tissue using 8 increasing concentrations of DAMGO. It is
possible that by increasing the highest concentration of DAMGO and expanding our ligand
binding curve we would reveal Bmax values that more closely resemble our autoradiography
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results (i.e., binding values of adult males and females continue to increase, while bound
DAMGO in the aged females remains comparatively plateaued). However, it is also possible that
the DAMGO binding values seen in the adult and aged female autoradiographs were due to nonspecific binding. As the specific binding curves calculated with the radioligand binding assay
were generated by removing non-specific binding, these values are more specific for MOR and
thus better represent functional receptor.
The radioligand binding assay provides an important distinction between receptor
availability (the total number of functional receptors to which agonist may bind; Bmax) and
receptor affinity (the strength of the agonist-receptor interaction; Kd). Our results indicate that
advanced age and sex do not impact MOR affinity, as evidenced by no significant differences
between Kd values. This suggests that unit receptor performance is not impacted in the aged
vlPAG and that the changes imparted as a function of advanced age and sex are at the level of
receptor downregulation rather than desensitization (Williams et al., 2013).
Previous studies examining the impact of advanced age on MOR binding report reduced
MOR in the frontal cortex and striatum of aged male rats (Hess et al., 1981; Messing et al., 1981)
and reduced MOR in the midbrain and thalamus of aged female rats (Messing et al., 1980).
These studies support our findings (Chapters 2 & 3) and suggest age-induced downregulation of
MOR in a sex- and site-specific manner. A recent clinical study using [11C]carfentanil positron
emission tomography reported that MOR binding in the thalamus, amygdala, and nucleus
accumbens is reduced in aged males and females compared to young adults (Kantonen et al.,
2020). Unfortunately, this study did not measure MOR binding in the PAG. In contrast,
Kantonen et al. (2020) reported age-induced increases in MOR binding in the cingulate cortex,
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orbitofrontal cortex, and temporal pole, indicating region-specific changes in MOR binding as a
function of age.
Taken together, these findings suggest that MOR binding is downregulated in the aged brain
in a region-specific manner. To determine if PAG MOR is downregulated in the aged as a
function of age-induced changes in OPRM1 transcription, we used in situ hybridization.
Quantification of OPRM1 transcripts and OPRM1+ neurons revealed no impact of advanced age
on vlPAG OPRM1 mRNA expression suggesting that OPRM1 transcription within the vlPAG is
not altered as a function of advanced age. Thus, although aged animals exhibit reduced MOR
protein within the vlPAG compared to young adult rats, these deficits are not present in MOR
mRNA and suggest that the reduction in vlPAG MOR protein is a function of impaired
translation. Ori et al. (2015) compared RNA sequencing and ribosome profiling on 6 month old
vs 24 months old rats and reported reduced expression of several markers necessary to initiate
translation, namely EIF3A, EIF4G3, EIF4A1, and MDN1, in aged rats (Ori et al., 2015).
Additionally, tissue from aged rats exhibited reduced levels of several markers that contribute to
ribosomal regulation of translation, including BCCIP, Ngdn, RtCD1, and BOP1 (Ori et al.,
2015). A study using C. elegans also reports that aging is associated with imbalanced protein
regulation and increased mRNA degradation (Walther et al., 2015). However, if aged rats exhibit
dysregulated translation of OPRM1 in the vlPAG is not known. The use of active mRNA
translation sequencing or ribosome profiling to measure the rate of protein synthesis in specific
brain regions will provide further insight into the impact of advanced age on MOR expression
and availability.
No impact of persistent inflammatory pain on MOR expression or binding in the vlPAG was
noted in the present studies. Our findings are in line with previous reports of no change in PAG
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MOR availability or expression in adult male rats experiencing neuropathic pain (Thompson et
al., 2018). This study did report reduced levels of MOR in the caudate-putamen and insula
(Thompson et al., 2018). Intraplantar CFA has been shown to increase MOR binding in the
dorsal root ganglia of adult male Wistar rats (Mousa et al., 2001; Zollner et al., 2003), but have
no impact on MOR binding in the hypothalamus (M. A. Shaqura et al., 2004), suggesting that
persistent inflammatory pain influences MOR binding in a region-specific manner.
Clinically, MOR binding is typically assessed using positron emission tomography (PET)
measurements following administration of opioid agonists in the presence and absence of
naloxone. Reduced MOR binding was reported in the straight gyrus and the frontal, temporal,
and cingulate cortices of males and females experiencing rheumatoid arthritis pain (Jones et al.,
1994); no change was found in the PAG. An additional study reported decreased MOR binding
in the nucleus accumbens, amygdala, and cingulate cortex of females experiencing fibromyalgia
pain, but the PAG was not included as a region of interest (Harris et al., 2007). No change in
PAG MOR binding was noted in men experiencing chronic pain induced by proximal nerve
injury (Maarrawi et al., 2007), however, neuropathic pain generated from a supraspinal injury
was associated with reduced PAG MOR binding (Maarrawi et al., 2007). Together, these clinical
findings suggest that the impact of pain on MOR binding is dependent on the modality of pain
and the brain region examined. It is not known whether surgical pain or pain following a
traumatic injury impacts PAG MOR expression or binding in humans.
We report no sex differences in vlPAG MOR expression, a finding that contradicts
previous results from our lab in which adult females exhibited reduced vlPAG MOR compared
to males (Loyd et al., 2008). These contradictory results are likely due to methodological
differences, and in particular, differences in antibody specificity and assessment of MOR density
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from images acquired using a 3-dimensional confocal versus 2-dimensional light-field
microscope. The lack of sex differences in PAG MOR expression found using
immunohistochemistry was corroborated by our MOR saturation binding studies. These findings
suggest that the reduced morphine potency seen in adult females compared to adult males is not
driven by changes in vlPAG MOR availability as previously proposed (Loyd et al., 2008), but
rather an alternative mechanism or mechanisms. Studies from our lab and others suggest that sex
differences in neuroimmune signaling, particularly in microglia, contribute to the sexually
dimorphic effects of morphine (Sorge et al., 2011; Eidson et al., 2017; Doyle & Murphy, 2017;
Rosen et al., 2017; Eidson & Murphy, 2019). Morphine binds to neuronal MOR as well as to the
innate immune receptor toll-like receptor 4 (TLR4), localized primarily on microglia
(Hutchinson et al., 2007, 2008, 2010). Morphine promotes TLR4-mediated downregulation of
GABA receptors and glutamate transporters (GLT1 and GLAST) and upregulation of AMPA
receptors. These changes result in an overall increase in neural excitability, promoting
depolarization and directly opposing morphine analgesia (Chieng & Christie, 1996; Ingram et al.,
1998; Song & Zhao, 2001; Ogoshi et al., 2005; Stellwagen et al., 2005; Holdridge et al., 2007; X.
Wang et al., 2012; Eidson et al., 2017). Activation of TLR4 via lipopolysaccharide results in
increased pro-inflammatory IL-1ß and decreased anti-inflammatory IL-10 within the vlPAG of
female but not male rats, and blockade of vlPAG TLR4 signaling via (+)-naloxone enhances
morphine analgesia in females but not in males (Doyle et al., 2017), suggesting a sex-dependent
mechanism for reduced opioid potency that is independent of PAG MOR. Neuroinflammation
has been linked to many conditions concomitant with advanced age as well, suggesting that aged
animals exhibit aberrant neuroimmune signaling (Gorelick, 2010; VanGuilder et al., 2011;
Norden & Godbout, 2013). Thus, neuroinflammation via TLR4 activation may act in tandem
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with changes in MOR binding and signaling to attenuate opioid analgesia in aged males and
females.
To further elucidate the mechanisms by which advanced age and sex alter opioid
analgesia, future studies should assess MOR expression and binding in additional regions along
the descending modulatory tract. While the present studies represent a comprehensive
assessment of MOR within the vlPAG, immunohistochemistry, autoradiography, and receptor
binding assays performed on RVM and spinal cord tissue from rodents in a chronic pain state
will further our knowledge of the impact of advanced age and sex on opioid analgesia.
4.3

Advanced age and sex modulate vlPAG MOR signaling
4.3.1

G-protein activation

Figure 4.2 DAMGO-induced G-protein activation
DAMGO binding induces a conformational change in the MOR, promoting the
dissociation of the Gαβγ complex, and subsequent activity at downstream effectors such as AC

G-protein-mediated signaling is critical for opioid-induced hyperpolarization (Laugwitz
et al., 1993; Connor & Christie, 1999; Koehl et al., 2018). We report that adult males exhibit
greater G-protein activation efficiency compared to aged males and adult and aged females
(Chapter 3). A significant impact of biological sex on G-protein potency (EC50) was also
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observed; females of both ages exhibited increased EC50 values compared to males, indicating a
reduction in the potency of opioid-dependent G-protein activation. This reduction in vlPAG Gprotein activation likely contributes to our result (Chapter 2) and the findings of previous studies
that females are less sensitive to the analgesic effects of opioids (Kest et al., 2000; Loyd et al.,
2008; Y.-J. Wang et al., 2014). Whether these findings suggest an additional mechanism
responsible for reduced opioid analgesia is not clear. The GTPγS assay uses membrane
preparations; therefore, soluble signaling regulators (like kinases) are not present. In addition, the
GTPS molecule itself is not hydrolyzable, and thus not regulated by GTPase-activating proteins
(GAPs) such as RGS proteins (Strange, 2010). Therefore, the observed decrease in G-protein
activation in the aged and adult females may be a result of the reduced opioid receptor
expression/availability as noted in the autoradiography and radioligand binding studies (Chapters
2 and 3).
Our findings indicate reduced opioid-stimulated G-protein signaling within the PAG of
aged and female rats. This reduced activation of downstream G-proteins may be due in part to
age-induced downregulation of PAG Gi/o, or an uncoupling of MOR from Gi/o associated with
aging. Several previous studies have reported an age-induced downregulation of Gi/o in the
prefrontal cortex (Young et al., 1991; Alemany et al., 2007; de Oliveira et al., 2019) and the
hippocampus, substantia nigra, and striatum in humans (de Oliveira et al., 2019). Whether Gαi/o
expression is reduced in the PAG is not known, and thus further experimentation is needed to
confirm the site-specificity of the observed age-induced downregulation. Age-induced
uncoupling of MOR from Gi/o would reduce opioid-stimulated G-protein activation without
changes in Gi/o tissue expression. Further, advanced age and/or biological sex may promote
aberrant MOR-G-protein coupling in which MOR couples to the excitatory Gαs rather than the

92
inhibitory Gi/o (Gintzler & Chakrabarti, 2000, 2004, 2006). A shift from Gi/o to Gs would
produce adenylate cyclase activation (rather than the requisite inhibition), resulting in cAMPmediated depolarization and thus decreased opioid response (Lamberts et al., 2011).
Experimentation assessing the impact of advanced age and sex on the expression and coupling of
Gα isoforms would further elucidate the mechanisms whereby advanced age and sex attenuate
opioid-induced G-protein activation.
The present studies used the high-affinity MOR agonist DAMGO for both the radioligand
binding and GTPyS assay. Previous studies have reported that MOR pharmacodynamics are
agonist-dependent; namely, MOR phosphorylation induced by morphine exposure is protein
kinase C (PKC)-dependent, while DAMGO-induced MOR phosphorylation is PKC independent
(Chu et al., 2010). Additionally, MOR is internalized by DAMGO and fentanyl binding, but not
by morphine (Hashimoto & Kirihara, 2006). Therefore, future studies should consider
incorporating at least two agonists in all assays to ensure any results are not ligand-dependent.
Alternatively, advanced age may promote the expression of OPRM1 splice variants (Alvarez et
al., 2002; Pan et al., 2005; Narayan et al., 2021). Alternative MOR isoforms are known to
promote ligand-dependent regulation of opioid signaling (D. A. Pasternak et al., 2004; Oldfield
et al., 2008). For example, variants of MOR-1B, a family of MOR isoforms expressed in the
brain, are indistinguishable from MOR-1 at the extracellular surface and the agonist binding
pocket but elicit alternative signaling properties that impact opioid-induced cell
hyperpolarization, and dysregulation of these MOR splice variants has been implicated in
advanced age (Latorre & Harries, 2017; H. Li et al., 2017; K. Wang et al., 2018). There are also
reports of sex differences in the expression of MOR splice variants in the PAG, with male
rodents expressing higher levels of MOR-1B5 and females expressing higher levels of MOR-
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1B1 and MOR-1B2 (A. Liu et al., 2018). The unique conformation of MOR isoforms and
subsequent alterations in receptor phosphorylation directly influence the G-proteins to which
MORs couple, potentially resulting in biased agonism as a function of advanced age (Pan et al.,
2005; Verzillo et al., 2014; Abrimian et al., 2021).
Our data (Chapter 3) indicate that CFA-treated rats exhibited reduced EC50 values, and
thus increased G-protein activation efficiency, compared to handled rats, regardless of age or
sex. These findings suggest that persistent inflammatory pain alters DAMGO-induced G-protein
activation within the PAG. One study performed on male rats reported that Ga subunit
expression is reduced in the RVM and dorsal horn of the spinal cord following intraplantar CFA
(Wattiez et al., 2017), suggesting reduced DAMGO-induced G-protein activation in these
regions. However, no impact of CFA on Ga subunit expression in the vlPAG was found. Thus,
the mechanism whereby intraplantar CFA enhances G-protein activation is not known.
4.3.2

MOR phosphorylation

MOR desensitization is canonically mediated by G-protein-coupled receptor kinase
(GRK)-dependent phosphorylation of the receptor, a mechanism by which β-arrestins bind to
MOR, resulting in endocytosis (L. Zhang et al., 1996; Yu et al., 1997; J. Zhang et al., 1998;
Schulz et al., 2004; Dang et al., 2009; Groer et al., 2011). The present studies tested the
hypotheses that the observed reductions in G-protein activation efficiency were due to age- and
sex-induced changes in basal or constitutive MOR phosphorylation by examining the
phosphorylation state of serine-375 on PAG MOR in the absence of opioid agonist binding. We
report no significant impact of age or sex on MOR basal phosphorylation (Chapter 3), suggesting
that the reductions in G-protein activation potency observed in the vlPAG of aged and female
rats are driven by an alternative mechanism.
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In addition to GRK phosphorylation at Ser375 studies on rat MOR indicated that
constitutive phosphorylation of the receptor is carried out by CAMKII phosphorylation at
Thr370 and PKC phosphorylation at Ser363 (Chen et al., 2013; Lemel et al., 2020). MOR is also
desensitized is via phosphorylation through the extracellular signal-regulated kinase 1 and 2
(ERK1/2) pathway, in which ERK1/2 phosphorylation stimulates the activity of Gα-interacting
protein (GAIP), an RGS protein that acts as a GTPase activator to reduce opioid signaling at the
level of G-protein activation (Ogier-Denis et al., 2000; Dang et al., 2009; Melkes et al., 2020).
This mechanism has been shown to contribute to opioid signaling, as pharmacological inhibition
of ERK1/2 phosphorylation enhances morphine analgesia in a rat model of neuropathic pain
(Popiolek-Barczyk et al., 2014). Thus, age- and/or sex-induced hyper-phosphorylation of
ERK1/2 may result in reduced G-protein signaling and attenuated morphine potency observed in
aged males and females.
In addition to lending insight into age-induced changes in G-protein signaling,
investigation of MOR splice variant expression in the aged brain will provide insight into the
mechanisms responsible for alternative receptor phosphorylation in the aged. The unique
conformation of MOR isoforms promotes alternative receptor phosphorylation and influences
biased agonism (Verzillo et al., 2014; Abrimian et al., 2021). Recent studies reported that
multiple MOR splice variants, specifically MOR-1O, exhibit significant biases for β-arrestin2,
suggesting that overexpression of certain MOR isoforms proteins promotes divergent opioid
signaling processes (Xu et al., 2017; Narayan et al., 2021).
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4.3.3

Opioid-induced cAMP inhibition

Opioid-induced G-protein mediated adenylyl
cyclase (AC) inhibition plays a critical role in opioid
analgesia. Exogenous opioids such as morphine
hyperpolarize neurons in part by inhibiting the conversion
of adenosine triphosphate (ATP) to cAMP (Christie, 2008;
Santhappan et al., 2015). The present studies examine the
hypothesis that the reduced opioid potency observed in our
behavioral experiments is due to attenuated opioidinduced cAMP inhibition within the vlPAG of aged males

Figure 4.3 Opioid-induced cAMP
inhibition
MOR binding induces Gai/o
activation, promoting inhibition of AC and
thus reduced cAMP

and females regardless of age. In these studies, we used forskolin stimulation to boost cAMP
levels in PAG tissue lysates and examined the impact of age and sex on the ability of DAMGO
to inhibit AC-mediated cAMP production. Our results show that aged males and females
(regardless of age) exhibit reduced DAMGO-induced cAMP inhibition compared to adult males,
indicating attenuated downstream MOR signaling in the aged PAG. This attenuation may be due
to the observed decreases in MOR availability and activation potency discussed above.
Additionally, the reduced efficacy of DAMGO to inhibit cAMP may be due to advanced ageand sex-induced alterations to AC signaling mechanisms, such as aberrant phosphorylation of
AC as a function of age (Yoshimasa et al., 1987). The observed reductions in DAMGO-induced
cAMP inhibition may also be driven by dysregulated cAMP circulation via cAMP hydrolysis by
phosphodiesterases (PDEs) (Goraya & Cooper, 2005). Indeed, expression of hydrolyzing PDEs
PDE1C and PDE8A is increased in the striatum of aged rats (26 mos) compared to adults (5
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mos). Further, PDE8A and PDE11A expression are increased in the hippocampus of aged rats,
and PDE1C expression is increased in the cortex (Kelly et al., 2014).
Interestingly, previous studies have reported that basal cAMP levels are reduced in
several brain regions of the aged male rats, including the cerebral cortex, midbrain-thalamus, and
hypothalamus (Puri & Volicer, 1981; Titus et al., 2013; Kelly, 2018). However, these same
studies reported no change in basal cAMP levels in the striatum, cerebellum, or hippocampus,
suggesting the effects of aging on cAMP levels are region-specific. The impact of advanced age
on basal cAMP levels within the rat vlPAG has not previously been addressed. Age-induced
cAMP reduction within the vlPAG would likely result in a more effective DAMGO-induced
cAMP inhibition, which is in direct contrast to our observed reduction in opioid potency.
However, our present studies that measured forskolin-boosted cAMP suggest slight reductions in
basal cAMP in the aged vlPAG, but only DAMGO-induced cAMP inhibition was statistically
analyzed.
Previous studies assessing the impact of advanced age on cAMP were conducted
exclusively in male rodents; thus, it is not known whether advanced age impacts cAMP signaling
in both aged males and females. One recent study reported an impact of biological sex on kappa
opioid receptor (KOR) signaling in the mouse spinal cord using a model of surgical pain,
reporting that KOR signaling in males is PKA-dependent and KOR signaling in females is PKAindependent (Basu et al., 2021). It is not known, however, whether this sex difference is present
in MOR signaling within the vlPAG.
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Figure 4.4 DAMGO-induced cAMP inhibition and βγ signaling
Opioid-induced Gai/o activation promotes AC-mediated cAMP inhibition, GIRKmediated hyperpolarization, and calcium channel inhibition
Morphine binding to MOR results in the activation of Gai/o that primarily inhibits the
activity of AC, thereby reducing cAMP production; in parallel, the βγ subunits activate G-protein
inwardly rectifying potassium (GIRK) channels to induce hyperpolarization and decrease
excitability (Law et al., 2000; Nobles et al., 2005; Yudin & Rohacs, 2018)(Figure 4.3).
Advanced age is concomitant with increased levels of neuroinflammation and greater production
of reactive oxygen species (ROS), both of which have been implicated in age-induced potassium
channel dysfunction (Sparkman & Johnson, 2008; Cai & Sesti, 2009; Sesti, 2016; Lieberman et
al., 2020). Consistent with this, aged Sprague Dawley rats (26-30 mos) exhibit reduced
potassium currents in hippocampal neurons, with no effect of age on neuronal density or cell
integrity (Alshuaib et al., 2001). The authors suggested that the observed reduction in potassium
current is due to either age-induced alteration in potassium channel kinetics, or reduced density
(number) of potassium channels. Taken together, these findings suggest that advanced age may
induce aberrant GIRK channel-mediated hyperpolarization within the PAG, thereby limiting
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opioid signaling in this region, and contributing to the reduced morphine potency observed in
aged rats.
4.3.4

RGS protein expression

Opioid-induced G-protein signaling is modulated by the activity of Regulator of Gprotein signaling (RGS) proteins (Cabrera-Vera et al., 2003; Xie & Palmer, 2005; Senese et al.,
2020). Two members of the RGS protein family have been extensively studied for their role in
regulating opioid signaling: RGS4 and RGS9-2. The overexpression of RGS4 attenuates MOR
signaling in reconstituted MORs in vitro (Ippolito et al., 2002), and conversely, knockout of
RGS9-2 enhances morphine analgesia (Garzón et al., 2001; Zachariou et al., 2003); thus,
expression of RGS4 and RGS9-2 negatively correlates with opioid analgesia.
Our final experiments examined the hypothesis that age and sex-mediated changes in
vlPAG RGS4 and RGS9-2 contribute to the reduced opioid potency observed in aged and female
rats. In these studies, RNAscope was performed on vlPAG tissue sections from adult and aged,
male and female rats. Our results showed increased vlPAG expression of both RGS4 and RGS92 in aged rats compared to adults. Increased expression of both RGS4 and RGS9-2 was specific
for MOR+ neurons within the vlPAG, providing a mechanism by which advanced age could
decrease analgesic potency and downstream cAMP signaling. However, as there was no
difference in RGS expression as a function of sex in adults, these data do not explain why adult
females demonstrate lower potency and signaling than adult males. These findings are consistent
with Kim et al. (2005) who assessed the impact of advanced age using male Sprague Dawley rats
and reported increased RGS9-2 expression within the PAG at 1 year vs 3 weeks (Kim et al.,
2005).
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To date, there is limited study on the impact of advanced age on RGS4 and RGS9-2
expression in the CNS. A clinical study of postmortem brain tissue of individuals aged 15-88
years used western blotting to examine age and sex differences in RGS4 along with RGS10, a
protein whose dysregulation is implicated in neurodegenerative disorders such as Parkinson's
disease and multiple sclerosis. Rivero et al. (2010) reported increased RGS4 expression in the
pre-frontal cortex of aged brains, while no impact of advanced age on RGS10 was observed
(Rivero et al., 2010). Unfortunately, the pre-frontal cortex was the only region examined so the
impact of advanced age on RGS4 and RGS10 in other brain regions is unknown. Taken together
with our findings, these data suggest that RGS4 expression is increased in multiple brain regions
as a function of advanced age and identify RGS4 as a potential target for novel therapeutic
strategies for improved opioid signaling in the elderly.
RGS proteins represent an interesting perspective for targeted therapy as their
downregulation via specific pharmacological inhibitors could potentiate opioid analgesia, and as
such, several RGS protein inhibitors have been developed. Recent studies have reported that
intrathecal inhibition of RGS4 enhances the analgesic effects of opioids (Yoon et al., 2015).
Interestingly, administration of intrathecal RGS4 inhibitors reduces hyperalgesia in the absence
of opioids, suggesting RGS regulation of endogenous opioids (Bosier et al., 2015; Yoon et al.,
2015). Taken together with our results (Chapter 3) these findings suggest that inhibition of RGS4
within the PAG may improve the pain-relieving properties of morphine following CFA injection.
Based on our finding that RGS4 expression is upregulated in the aged PAG, we predict that
pharmacological inhibition of vlPAG RGS4 in aged rats would amplify MOR signaling in this
region and enhance morphine analgesia.
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